

REFERENCIAS BIBLIOGRÁFICAS

Capítulo 1

1. Hoang, Mai P. y Selim, Maria Angelica. *Vulvar Pathology*. New York : Springer, 2015.
2. *Embriología del Aparato Genital Femenino*. Barriere, P., Mirallie, S. y Jean, M. 4, 2000, EMC - Ginecología-Obstetricia, Vol. 36, págs. 1-11.
3. Wilkins , Edward J.; Hardt, Nancy S. Vulva. [book auth.] Stacey E. Mills. *Histology for Pathologists*. s.l. : Lippincott Williams & Wilkins, 2012, pp. 1045-1058.
4. *Morphologic and Physiological Changes of Genital Skin and Mucosa*. Farage, Miranda A. y Maibach, Howard I. s.l. : Karger, 2011, Curr Probl Dermatol, Vol. 40, págs. 9-19.
5. *Normal Vulvar Histology: Variation by Site*. Day, T., Holland, SM y Scurry, J. 1, Jan de 2016, J Low Genit Dis, Vol. 20, págs. 64-69.

REFERENCIAS BIBLIOGRÁFICAS

Capítulo 2

1. Lynch P, Moyal-Barraco M, Scurry J, Stockdale C. 2011 ISSVD Terminology and Classification of Vulvar Dermatological Disorders: An Approach to Clinical Diagnosis. J Low Genit Tract Dis. 2012 Oct;16(4):339-44.
2. Cohen Sacher B. The Normal Vulva, Vulvar Examination, and Evaluation Tools. Clin Obstet Gynecol. 2015 Sep;58(3):442-52.
3. Stockdale C, Boardman L. Diagnosis and treatment of vulvar dermatoses. Obstet Gynecol. 2018 Feb;131(2):371-386
4. Lancheros L, Palma F (dir). (2011). Consenso de semiología dermatológica Universidad Nacional de Colombia. [Trabajo final de grado en internet]. [Bogotá]. Universidad Nacional de Colombia. [Citado 16 de Mayo de 2018] Recuperado a partir de: <http://bdigital.unal.edu.co/7161/1/598069.2011.pdf>
5. Bologna, J., Jorizzo, J. L., & Schaffer, J. V. (2012). *Dermatology*. Philadelphia: Elsevier Saunders.

REFERENCIAS BIBLIOGRÁFICAS

Capítulo 3

1. Nischal U, Nischal K, Khopkar U. Techniques of skin biopsy and practical considerations. J Cutan Aesthet Surg. 2008;1(2):107.
2. Yang S, Kampp J. Common Dermatologic Procedures. Med Clin North Am. 2015;99(6):1305-21.
3. Mayeaux EJ, Cooper D. Vulvar procedures: Biopsy, bartholin abscess treatment, and condyloma treatment. Obstet Gynecol Clin North Am. 2013;40(4):759-72.
4. Alguire PA MB. A Biopsy Is More Than a Biopsy. J Gen Intern Med. 1998;13(1):62,63.
5. Llamas-Velasco M, Paredes BE. La biopsia cutánea: bases fundamentales. Parte I. Actas Dermosifiliogr. 2012;103(2):100-10.
6. Silverstein D, Mariwalla K. Biopsy of the Pigmented Lesions. Dermatol Clin. 2012;30(3):435-43
7. Goldman G. The current status of curettage and electrodesiccation. Dermatol Clin. 2002;20(3):569-78.
8. Stewart KMA. A Clinical Approach to Vulvar Ulcers. Obstet Gynecol Clin North Am. 2017;44(3):445-51.
9. Navarrete-Dechent C, Moll-Manzur C, Droppelmann N, González S. Actualización en el uso de la biopsia de piel por punch. Rev Chil Cirugía. 2016;68(6):467-73.

REFERENCIAS BIBLIOGRÁFICAS

Capítulo 4

1. van Eijk, A. M., Sivakami, M., Thakkar, M. B., Bauman, A., Laserson, K. F., Coates, S., & Phillips-Howard, P. A. (2016). Menstrual hygiene management among adolescent girls in India: a systematic review and meta-analysis. *BMJ open*, 6(3), e010290. <https://doi.org/10.1136/bmjopen-2015->
2. Vivo positivo: Coordinadora Nacional de Agrupaciones y Organizaciones de Personas Viviendo con VIH/Sida. Santiago, Chile. Abril 2015.
3. Britz, M. B., & Maibach, H. I. (1979). Human labia majora skin: transepidermal water loss in vivo. *Acta dermato-venereologica. Supplementum*, 59(85), 23–25.
4. Elsner, P., Wilhelm, D., & Maibach, H. I. (1990). Physiological skin surface water loss dynamics of human vulvar and forearm skin. *Acta dermato-venereologica*, 70(2), 141–144.
5. Potts, R. O., & Guy, R. H. (1992). Predicting skin permeability. *Pharmaceutical research*, 9(5), 663–669. <https://doi.org/10.1023/a:1015810312465>
6. Oriba, H. A., Bucks, D. A., & Maibach, H. I. (1996). Percutaneous absorption of hydrocortisone and testosterone on the vulva and forearm: effect of the menopause and site. *The British journal of dermatology*, 134(2), 229–233.
7. Beecker J. (2010). Therapeutic principles in vulvovaginal dermatology. *Dermatologic clinics*, 28(4), 639–648. <https://doi.org/10.1016/j.det.2010.07.001>
8. Harvell, J., Hussona-Saeed, I., & Maibach, H. I. (1992). Changes in transepidermal water loss and cutaneous blood flow during the menstrual cycle. *Contact dermatitis*, 27(5), 294–301. <https://doi.org/10.1111/j.1600-0536.1992.tb03283.x>.
9. van der Bijl, P., Thompson, I. O., & Squier, C. A. (1997). Comparative permeability of human vaginal and buccal mucosa to water. *European journal of oral sciences*, 105(6), 571–575. <https://doi.org/10.1111/j.1600-0722.1997.tb00219.x>.
10. Squier, C. A., Cox, P., & Wertz, P. W. (1991). Lipid content and water permeability of skin and oral mucosa. *The Journal of investigative dermatology*, 96(1), 123–126. <https://doi.org/10.1111/1523-1747.ep12515931>.

REFERENCIAS BIBLIOGRÁFICAS

11. Edwards, J. N., & Morris, H. B. (1985). Langerhans' cells and lymphocyte subsets in the female genital tract. *British journal of obstetrics and gynaecology*, 92(9), 974–982. <https://doi.org/10.1111/j.1471-0528.1985.tb03080.x>
12. Miller, C. J., McChesney, M., & Moore, P. F. (1992). Langerhans cells, macrophages and lymphocyte subsets in the cervix and vagina of rhesus macaques. *Laboratory investigation; a journal of technical methods and pathology*, 67(5), 628–634..
13. Margesson L. J. (2004). Contact dermatitis of the vulva. *Dermatologic therapy*, 17(1), 20–27. <https://doi.org/10.1111/j.1396-0296.2004.04003.x>
14. Schlosser B. J. (2010). Contact dermatitis of the vulva. *Dermatologic clinics*, 28(4), 697–706. <https://doi.org/10.1016/j.det.2010.08.006>.
15. Kuehl, B. L., Fyfe, K. S., & Shear, N. H. (2003). Cutaneous cleansers. *Skin therapy letter*, 8(3), 1–4.
16. Hábitos higiénicos vulvovaginales de consultantes ambulatorias en ginecoobstetricia. *rev chil obstet ginecol* (2015); 80(4):282-288.
17. Cuevas A, Celis C, Hernández H, Paradas *et al.* (GRUPO MASIM). Resultados de una encuesta epidemiológica de hábitos de higiene íntima en mujeres latinoamericanas. *Rev Obstet Ginecol Venez* (2011); 7(1):21-7.
18. Effendy I. Surfactants and experimental irritant contact dermatitis. *Contact Dermatitis*, (1995); 33:217-225.
19. Friedman M. Chemistry of soaps and detergents: various types of commercial products and their ingredients. *Cllin Dermatol*.1996;14:7-13.
20. Fisher GO. The coomonest causes of symptomatic vulvar disease: A dermatologist perspective. *Australas J Dermatol* (1996);37:12-18.
21. Miranda A. Farage. Vulvar susceptibility to contact irritants and allergens: a review. *Arch Gynecol Obstet*(2005) 272:167-172.
22. Barany E. Biophysical characterization of skin damage and recovery after exposure to different surfactants. *Contact Dermatitis* (1999);40:98-103.
23. Cruz Garnica AP, Salamanca S, Hernández N, Villamil JA, Quiasua DC. Dermatitis de contacto alérgica e irritativa en región vulvar. Impacto de los jabones íntimos. *rev. asoc. colomb. dermatol. cir. dematol.* [Internet]. 28 de abril de 2020 [citado 27 de octubre de

REFERENCIAS BIBLIOGRÁFICAS

- 2021];27(4):239-58. Disponible en:
<https://revista.asocolderma.org.co/index.php/asocolderma/article/view/1398>.
24. Ruiz C, Giraldo PC, Sánchez JM, Reis V, Beghini J, Laguna C, Amaral RL. Daily genital cares of female gynecologists: a descriptive study. *Rev Assoc Med Bras* (1992). 2019 Feb;65(2):171-176. doi: 10.1590/1806-9282.65.2.171. PMID: 30892440.
25. Monin L, Whettlock EM, Male V. Immune responses in the human female reproductive tract. *Immunology*. 2020 Jun;160(2):106-115. doi: 10.1111/imm.13136. Epub 2019 Nov 11. PMID: 31630394; PMCID: PMC7218661.
26. Swain, T. A., Tully, A. S., Redford, T., & McGwin, G. (2016). Hair removal-related injuries in the United States, 1991-2014. *Journal of cosmetic dermatology*, 15(4), 444-451. <https://doi.org/10.1111/jocd.12283>
27. Klann, A. M., Rosenberg, J., Wang, T., Parker, S. E., & Harlow, B. L. (2019). Exploring Hygienic Behaviors and Vulvodynia. *Journal of lower genital tract disease*, 23(3), 220-225. <https://doi.org/10.1097/LGT.0000000000000477>
28. Rodriguez, K. J., Cunningham, C., Foxenberg, R., Hoffman, D., & Vongsa, R. (2020). The science behind wet wipes for infant skin: Ingredient review, safety, and efficacy. *Pediatric dermatology*, 37(3), 447–454. <https://doi.org/10.1111/pde.14112>
29. Pontes, A. C., Amaral, R. L., Giraldo, P. C., Beghini, J., Giraldo, H. P., & Cordeiro, E. S. (2014). A systematic review of the effect of daily panty liner use on the vulvovaginal environment. *International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics*, 127(1), 1–5. <https://doi.org/10.1016/j.ijgo.2014.06.017>
30. Ó Briain, O., Marques Mendes, A. R., McCarron, S., Healy, M. G., & Morrison, L. (2020). The role of wet wipes and sanitary towels as a source of white microplastic fibres in the marine environment. *Water research*, 182, 116021. <https://doi.org/10.1016/j.watres.2020.116021>

REFERENCIAS BIBLIOGRÁFICAS

Capítulo 5

1. Kristen M.A. Stewart. Clinical Care of Vulvar Pruritus, with Emphasis on One Common Cause, Lichen Simplex Chronicus. *Dermatol Clin* 28 (2010) 669–680.
2. Lambert J. Pruritus in female patients. *Biomed research Int* 2014;541867.doy:10.1155/2014/541867. Epub 2014 Mar 10.
3. Wakashin K. Sanitary napkin contact dermatitis of the vulva: location-dependent differences in skin surface conditions may play a role in negative patch test results. *J Dermatol* 2007;34:834–7.
4. Carbotta G., Sallustio P., Presteria A., Laforgia R., Lobascio P., Palasciano N. Perineal Paget disease: A rare disorder and review literature. *Annals of Med nd Surg* 2016;9:50-52

REFERENCIAS BIBLIOGRÁFICAS

Capítulo 6

1. Ozalp SS, Telli E, Yalcin OT, Oge T, Karakas N. Vulval pruritus: the experience of gynaecologists revealed by biopsy. *J Obstet Gynaecol. England*; 2015 Jan;35(1):53–6.
2. Paek SC, Merritt DE, Mallory SB. Pruritus vulvae in prepubertal children. *J Am Acad Dermatol. United States*; 2001 May;44(5):795–802.
3. Ángel-Müller Edith, Rodríguez Andrea, Núñez-Forero Lilian M, Moyano Luisa F, González Patricia OE et al. Prevalencia y factores asociados a la infección Por *C. trachomatis*, *N. gonorrhoeae*, *T. vaginalis*, *C. albicans*, sífilis, VIH y vaginosis bacteriana en mujeres con síntomas de infección vaginal en tres sitios de atención de Bogotá, Colombia, 2010. *Rev Col Obs y Ginecol*. 2012;63(1):25–35.
4. Xu J, Sobel J. Antibiotic-associated vulvovaginal candidiasis. *Curr Infect Dis Rep*. 2003;5(6):481.
5. Novikova N, Yassievich E MP. Microscopy of stained smears of vaginal secretion in the diagnosis of recurrent vulvovaginal candidosis. 2002; 13(5):318-22. *Int J STD AIDS*. 2002;13(5):318–22.
6. Workowski, K. A., Bachmann, L. H., Chan, P. A., Johnston, C. M., Muzny, C. A., Park, I., Reno, H., Zenilman, J. M., & Bolan, G. A. (2021). Sexually Transmitted Infections Treatment Guidelines, 2021. *MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports*, 70(4), 1–187. <https://doi.org/10.15585/mmwr.rr7004a1> 7. Colombia. Ministerio de Salud y Protección Social, Colciencias, Universidad Nacional. Guía de Práctica Clínica para el abordaje sindrómico del diagnóstico y tratamiento de los pacientes con infecciones de transmisión sexual y otras infecciones del tracto genital. 2013. 1-642 p.
8. Nurbhai M, Grimshaw J, Watson M, Bond C, Mollison J, Ludbrook A. Oral versus intra-vaginal imidazole and triazole anti-fungal treatment of uncomplicated vulvovaginal candidiasis (thrush). *Cochrane database Syst Rev. England*; 2007 Oct;(4):CD002845.
9. Beikert FC, Le MT, Koeninger A, Technau K, Clad A. Recurrent vulvovaginal candidosis: focus on the vulva. *Mycoses. Germany*; 2011 Nov;54(6):e807-10.

Enfoque sindromático de la enfermedad vulvar

REFERENCIAS BIBLIOGRÁFICAS

10. Leitsch D. Recent Advances in the *Trichomonas vaginalis* Field. F1000Research. England; 2016;5.
11. Meites E, Gaydos CA, Hobbs MM, Kissinger P, Nyirjesy P, Schwebke JR, et al. A review of evidence-based care of symptomatic trichomoniasis and asymptomatic trichomonas vaginalis Infections. Clin Infect Dis. United States; 2015 Dec;61 Suppl 8:S837-48.
12. Bouchemal K, Bories C, Loiseau PM. Strategies for prevention and treatment of trichomonas vaginalis infections. Clin Microbiol Rev. United States; 2017 Jul;30(3):811–25.
13. Edwards T, Burke P, Smalley H, Hobbs G. *Trichomonas vaginalis*: Clinical relevance, pathogenicity and diagnosis. Crit Rev Microbiol. 2016;42(3):406–17.
14. Hirt RP. *Trichomonas vaginalis* virulence factors: an integrative overview. Sex Transm Infect. England; 2013 Sep;89(6):439–43.
15. Oliveira AS, Ferrao AR, Pereira FM, Martinez-de-Oliveira J, Palmeira-de-Oliveira A. *Trichomonas vaginalis*: An updated overview towards diagnostic improvement. Acta Parasitol. Poland; 2016 Jan;61(1):10–21.
16. Hay P, Czeizel A. Asymptomatic trichomonas and candida colonization and pregnancy. Best Pr Res Clin Obs Gynaecol. 2007;21(3):403–9.
17. Silver BJ, Guy RJ, Kaldor JM, Jamil MS, Rumbold AR. *Trichomonas vaginalis* as a cause of perinatal morbidity: a systematic review and meta-analysis. Sex Transm Dis. United States; 2014 Jun;41(6):369–76.
18. Hobbs MM, Sena AC. Modern diagnosis of *Trichomonas vaginalis* infection. Sex Transm Infect. England; 2013 Sep;89(6):434–8.
19. Gaydos CA, Klausner JD, Pai NP, Kelly H, Coltart C, Peeling RW. Rapid and point-of-care tests for the diagnosis of *Trichomonas vaginalis* in women and men. Sex Transm Infect. England; 2017 Dec;93(S4):S31–5.
20. Howe K, Kissinger PJ. Single-dose compared with multidose metronidazole for the treatment of trichomoniasis in women: A Meta-Analysis. Sex Transm Dis. United States; 2017 Jan;44(1):29–34.

Enfoque sindromático de la enfermedad vulvar

REFERENCIAS BIBLIOGRÁFICAS

21. Ministerio de Salud y Protección Social - Colciencias. Guía de Práctica Clínica (GPC) para el abordaje sindrómico del diagnóstico y tratamiento de los pacientes con infecciones de transmisión sexual y otras infecciones del tracto genital . 1ra. Bogotá; 2013. 640 p.
22. Lambert J. Pruritus in female patients. Biomed Res Int. United States; 2014;2014:541867.
23. Verstraelen H, Verhelst R, Vaneechoutte M, Temmerman M. Group A streptococcal vaginitis: an unrecognized cause of vaginal symptoms in adult women. Arch Gynecol Obstet. Germany; 2011 Jul;284(1):95–8.
24. Rimoin LP, Kwatra SG, Yosipovitch G. Female-specific pruritus from childhood to postmenopause: clinical features, hormonal factors, and treatment considerations. Dermatol Ther. United States; 2013;26(2):157–67.
25. Farrington P. Pediatric Vulvo-Vaginitis 1997; 40(1): 135-140. Clin Obs Gynecol. 1997;40(1):135–40.
26. Bragg BN, Simon L V. Pediculosis humanis (Lice, Capitis, Pubis). In treasure island (FL); 2017. PMID: 29262055
27. Salavastru CM, Chosidow O, Janier M, Tiplica GS. European guideline for the management of pediculosis pubis. Vol. 31, Journal of the European Academy of Dermatology and Venereology : JEADV. England; 2017. p. 1425–8.
28. Kimberly A. Workowski, Bolan GA. Sexually Transmitted Diseases Treatment Guidelines [Internet]. Vol. 64, Morbidity and Mortality Weekly Report (MMWR). 2015. 1-137 p. Available from: <http://www.cdc.gov/mmwr/preview/mmwrhtml/rr6403a1.htm>
29. Do-Pham G, Monsel G, Chosidow O. Lice. Semin Cutan Med Surg. United States; 2014 Sep;33(3):116–8.
30. Arlian LG, Morgan MS. A review of *Sarcoptes scabiei*: past, present and future. Parasit Vectors. England; 2017 Jun;10(1):297.
31. Engelman D, Kiang K, Chosidow O, McCarthy J, Fuller C, Lammie P, et al. Toward the global control of human scabies: introducing the International Alliance for the Control of Scabies. PLoS Negl Trop Dis. United States; 2013;7(8):e2167.

Enfoque sindromático de la enfermedad vulvar

REFERENCIAS BIBLIOGRÁFICAS

32. Micali G, Lacarrubba F, Verzi AE, Chosidow O, Schwartz RA. Scabies: Advances in noninvasive diagnosis. *PLoS Negl Trop Dis*. United States; 2016 Jun;10(6):e0004691.
33. Panahi Y, Poursaleh Z, Goldust M. The efficacy of topical and oral ivermectin in the treatment of human scabies. *Ann Parasitol*. Poland; 2015;61(1):11–6.
34. Hugot JP, Reinhard KJ, Gardner SL, Morand S. Human enterobiasis in evolution: origin, specificity and transmission. *Parasite*. France; 1999 Sep;6(3):201–8.
35. Carrillo-Quintero D, Del Otero Sanz L, Hernandez-Egido S, Martin Sanchez AM. [Demographic and clinical features of diagnosed individuals of enterobiasis in the southern Gran Canaria: sampling assessment]. *Rev Esp Quimioter*. Spain; 2016 Dec;29(6):302–7.
36. al-Rufaie HK, Rix GH, Perez Clemente MP, al-Shawaf T. Pinworms and postmenopausal bleeding. *J Clin Pathol*. England; 1998 May;51(5):401–2.
37. Leslie SW, Gossman WG. Wart, Genital. In *Treasure Island (FL)*; 2017. PMID: 28722914
38. Leszczyszyn J, Lebski I, Lysenko L, Hirnle L, Gerber H. Anal warts (condylomata acuminata) - current issues and treatment modalities. *Adv Clin Exp Med*. Poland; 2014;23(2):307–11.
39. Bhatia N, Lynde C, Vender R, Bourcier M. Understanding genital warts: epidemiology, pathogenesis, and burden of disease of human papillomavirus. *J Cutan Med Surg*. United States; 2013 Dec;17 Suppl 2:S47-54.
40. Cardoso JC, Calonje E. Cutaneous manifestations of human papillomaviruses: a review. *Acta dermatovenerologica Alpina, Pannonica, Adriat*. Slovenia; 2011 Sep;20(3):145–54.
41. Vender R, Bourcier M, Bhatia N, Lynde C. Therapeutic options for external genital warts. *J Cutan Med Surg*. United States; 2013 Dec;17 Suppl 2:S61-7.
42. Park IU, Introcaso C, Dunne EF. Human Papillomavirus and Genital Warts: A review of the evidence for the 2015 Centers for Disease Control and Prevention Sexually Transmitted Diseases Treatment Guidelines. *Clin Infect Dis*. United States; 2015 Dec;61 Suppl 8:S849-55.

Enfoque sindromático de la enfermedad vulvar

REFERENCIAS BIBLIOGRÁFICAS

REFERENCIAS BIBLIOGRÁFICAS

Capítulo 7

1. Torgenson R., Edwards L. Diseases and disorders of the female genitalia. In: Wolff K. Goldsmith L.A., Katz S.I., Gilchrest B.A., Paller A.S., Leffell D.J. editors. Fitzpatrick Dermatology 7^a edition. New York, Mc Graw Hill;2007.p.675-683
2. Marfatia Y, Surani A, Baxi R. Genital lichen sclerosis et atrophicus in females: An update. Indian J Sex Transm Dis 2019;40:6-12
3. F. R. Pérez-López & P. Vieira-Baptista (2017) Lichen sclerosis in women: a review, Climacteric, 20:4, 339-347, DOI: 10.1080/13697137.2017.1343295 Smith Y., Haefner H. Vulvar lichen sclerous. Am J Clinic Dermatol 2004;5(2):105-125
4. Tran DA, Tan X, Macri CJ, Goldstein AT, Fu SW. Lichen Sclerosus: An autoimmunopathogenic and genomic enigma with emerging genetic and immune targets. *Int J Biol Sci.* 2019;15(7):1429-1439. Published 2019 Jun 2. doi:10.7150/ijbs.34613
5. Lee A, Bradford J, Fischer G. Long-term Management of Adult Vulvar Lichen Sclerosus: a Prospective Cohort Study of 507 Women. JAMA Dermatol 2015; 151: 1061–1067
6. Lewis FM, Tatnall FM, Velangi SS, Bunker CB, Kumar A, Brackenbury F, et al. British association of dermatologists guidelines for the management of lichen sclerosis, 2018. Br J Dermatol 2018;178:839-53
7. Luis J. Borda, Marina Perper & Jonette E. Keri (2018): Treatment of Seborrheic Dermatitis: A Comprehensive Review, Journal of Dermatological Treatment, DOI: 10.1080/09546634.2018.1473554

REFERENCIAS BIBLIOGRÁFICAS

Capítulo 8

1. Marfatia, Y., Surani, A., & Baxi, R. (2019). Genital lichen sclerosus et atrophicus in females: An update. *Indian journal of sexually transmitted diseases and AIDS*, 40(1), 6–12. https://doi.org/10.4103/ijstd.IJSTD_23_19
2. Pérez-López, F. R., & Vieira-Baptista, P. (2017). Lichen sclerosus in women: a review. *Climacteric : the journal of the International Menopause Society*, 20(4), 339–347. <https://doi.org/10.1080/13697137.2017.1343295>.
3. Tran DA, Tan X, Macri CJ, Goldstein AT, Fu SW. Lichen Sclerosus: An autoimmune pathogenic and genomic enigma with emerging genetic and immune targets. *Int J Biol Sci*. 2019;15(7):1429-1439. Published 2019 Jun 2. doi:10.7150/ijbs.34613
4. Günthert AR¹, Duclos K, Jahns BG, Krause E, Amann E, Limacher A, Mueller MD, Jüni P. Clinical scoring system for vulvar lichen sclerosus. *J Sex Med*. 2012 Sep;9(9):2342-50. doi: 10.1111/j.1743-6109.2012.02814.x
5. Naswa S, Marfatia YS. Physician-administered clinical score of vulvar lichen sclerosus: A study of 36 cases. *Indian J Sex Transm Dis AIDS*. 2015;36(2):174–177. doi:10.4103/0253-7184.167169
6. Lewis FM, Tatnall FM, Velangi SS, Bunker CB, Kumar A, Brackenbury F, et al. British association of dermatologists guidelines for the management of lichen sclerosus, 2018. *Br J Dermatol* 2018;178:839-53
7. Castellano Cabrera, José. (2017). Uso adecuado de corticoides tópicos dermatológicos. *Boletín Canario de Uso Racional del Medicamento del SCS*. 8. 1-8.

REFERENCIAS BIBLIOGRÁFICAS

Capítulo 9

1. SHIFREN JL. Genitourinary Syndrome of Menopause. Clin Obstet Gynecol [Internet]. 2018;00(00):1. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/29787390> <http://Insights.ovid.com/crossref?an=00003081-9000000000-99603>
2. Eder SE. Early effect of fractional CO₂ laser treatment in Postmenopausal women with vaginal atrophy. Laser Ther [Internet]. 2018;27(1):41–7. Available from: https://www.jstage.jst.go.jp/article/islsm/27/1/27_18-OR-04/_article
3. Salvatore S, França K, Lotti T, Parma M, Palmieri S, Candiani M, et al. Early Regenerative Modifications of Human Postmenopausal Atrophic Vaginal Mucosa Following Fractional CO₂ Laser Treatment. Open Access Maced J Med Sci [Internet]. 2018;6(1):6. Available from: <https://www.idpress.eu/mjms/article/view/oamjms.2018.058>
4. Palacios S, Nappi RE, Bruyniks N, Particco M, Panay N. The European Vulvovaginal Epidemiological Survey (EVES): prevalence, symptoms and impact of vulvovaginal atrophy of menopause. Climacteric [Internet]. 2018;21(3):286–91. Available from: <https://doi.org/10.1080/13697137.2018.1446930>
5. Nappi RE, de Melo NR, Martino M, Celis-González C, Villaseca P, Röhrich S, et al. Vaginal Health: Insights, Views & Attitudes (VIVA-LATAM): results from a survey in Latin America. Climacteric [Internet]. 2018;0(0):1–7. Available from: <https://www.tandfonline.com/doi/full/10.1080/13697137.2018.1461826>
6. Palma F, Xholli A, Cagnacci A. The most bothersome symptom of vaginal atrophy: Evidence from the observational AGATA study. Maturitas [Internet]. 2018;108(October 2017):18–23. Available from: <http://dx.doi.org/10.1016/j.maturitas.2017.11.007>
7. Bachmann G. Urogenital ageing: an old problem newly recognized. Maturitas [Internet]. 1995;22:S1–5. Available from: [http://dx.doi.org/10.1016/0378-5122\(95\)00956-6](http://dx.doi.org/10.1016/0378-5122(95)00956-6)
8. Faubion SS, Sood R, Kapoor E. Genitourinary Syndrome of Menopause: Management Strategies for the Clinician. Mayo Clin Proc [Internet]. 2017;92(12):1842–9. Available

REFERENCIAS BIBLIOGRÁFICAS

- from: <https://doi.org/10.1016/j.mayocp.2017.08.019>
9. Mueck AO, Ruan X, Prasauskas V, Grob P, Ortmann O. Treatment of vaginal atrophy with estriol and lactobacilli combination: a clinical review. *Climacteric* [Internet]. 2018;21(2):140–7. Available from: <https://doi.org/10.1080/13697137.2017.1421923>
 10. Fernandes T, Pedro AO, Baccaro LF, Costa-Paiva LH. Hormonal, metabolic, and endometrial safety of testosterone vaginal cream versus estrogens for the treatment of vulvovaginal atrophy in postmenopausal women: A randomized, placebo-controlled study. *Menopause*. 2018;25(6):641–7.
 11. Llanea P, Calaf J, Jurado AR, Mendoza N, Otero B, Quereda F, et al. What do TSECs provide in the menopausal hormone therapy? *Gynecol Endocrinol* [Internet]. 2018;0(0):1–7. Available from: <https://www.tandfonline.com/doi/full/10.1080/09513590.2018.1474869>
 12. Pagano T, De Rosa P, Vallone R, Schettini F, Arpino G, Giuliano M, et al. Fractional microablative CO₂laser in breast cancer survivors affected by iatrogenic vulvovaginal atrophy after failure of nonestrogenic local treatments: A retrospective study. *Menopause*. 2018;25(6):657–62.
 13. Hersant B, Sidahmed-mezi M, Belkacemi Y, Darmon F, Bastuji-garin S, Werkoff G, et al. Efficacy of injecting platelet concentrate combined with hyaluronic acid for the treatment of vulvovaginal atrophy in postmenopausal women with history of breast cancer: a phase 2 pilot study. *Menopause*. 2018;25(10):1–7.
 14. González Isaza P, Jaguszewska K, Cardona JL, Lukaszuk M. Long-term effect of thermoablative fractional CO₂laser treatment as a novel approach to urinary incontinence management in women with genitourinary syndrome of menopause. *Int Urogynecol J*. 2018;29(2):211–5.
 15. González Isaza P, Ruiz Rosas AI, Vélez Rizo DL. Láser de CO₂fraccionado: un nuevo enfoque de tratamiento para incontinencia urinaria de esfuerzo (IUE) en mujeres posmenopáusicas. *Urol Colomb* [Internet]. 2017;26(1):8–11. Available from: <http://dx.doi.org/10.1016/j.uroco.2016.10.004>
 16. Torky HA, Taha A, Marie H, El-Desouky E, Raslan O, Moussa AA, et al. Role of topical

Enfoque sindromático de la enfermedad vulvar

REFERENCIAS BIBLIOGRÁFICAS

- oxytocin in improving vaginal atrophy in postmenopausal women: a randomized, controlled trial. *Climacteric* [Internet]. 2018;21(2):174–8. Available from: <https://doi.org/10.1080/13697137.2017.1421924>
17. D. Edwardsa and N. Panay. Treating vulvovaginal atrophy/genitourinary syndrome of menopause: how important is vaginal lubricant and moisturizer composition? *CLIMACTERIC*, 2015. <http://dx.doi.org/10.3109/13697137.2015.1124259>

REFERENCIAS BIBLIOGRÁFICAS

Capítulo 10

1. Das A, Panda S. Use of topical corticosteroids in dermatology: an evidence based approach. Indian J of Dermatol 2017, 62(3):237-250
2. Ballona CR. Corticoides tópicos en pediatría: Una puesta al día. Dermatología Peruana 2003;13(3):163-170
3. Valencia I, Kerdel F. Topical corticosteroids. In: Wolff K. Goldsmith L.A., Katz S.I., Gilchrest B.A., Paller A.S., Leffell D.J. editors. Fitzpatrick Dermatology 7^a edition. New York, Mc Graw Hill;2007.p.2102-2106
4. Rondon Lugo A. Buen uso de los esteroides topicos. Med Cut Ibero Lat Am 2013;41(6)245-53
5. Sheary B. Topical corticosteroids addiction and withdrawal – An overview for GPs. AFP 45 (6);2016:386-388
6. Torgenson R., Edwards L. Diseases and disorders of the female genitalia. In: Wolff K. Goldsmith L.A., Katz S.I., Gilchrest B.A., Paller A.S., Leffell D.J. editors. Fitzpatrick Dermatology 7^a edition. New York, Mc Graw Hill;2007.p.675-683

Capítulo 11

1. Kalia N, Singh J, Kaur M. Microbiota in vaginal health and pathogenesis of recurrent vulvovaginal infections: a critical review. *Ann Clin Microbiol Antimicrob*. 2020 Jan 28;19(1):5. doi: 10.1186/s12941-020-0347-4. PMID: 31992328; PMCID: PMC6986042.
2. Reichman O, Margesson LJ, Rasmussen CA, Lev-Sagie A, Sobel JD. Algorithms for Managing Vulvovaginal Symptoms-a Practical Primer. *Curr Infect Dis Rep*. 2019 Oct 8;21(10):40. doi: 10.1007/s11908-019-0693-6. PMID: 31595345.
3. Landers DV, Wiesenfeld HC, Heine RP, Krohn MA, Hiller SL. Predictive value of the clinical diagnosis of lower genital tract infection in women. *Am J Obstet Gynecol*. 2004;190:1004—10.
4. Malik, A. S., Porter, C. L., & Feldman, S. R. (2021). Bromhidrosis Treatment Modalities: A Literature Review. *Journal of the American Academy of Dermatology*, S0190-9622(21)00175-4. Advance online publication. <https://doi.org/10.1016/j.jaad.2021.01.030>
5. Vieira-Baptista, P., Grincevičienė, Š., Oliveira, C., Fonseca-Moutinho, J., Cherey, F., & Stockdale, C. K. (2021). The International Society for the Study of Vulvovaginal Disease Vaginal Wet Mount Microscopy Guidelines: How to Perform, Applications, and Interpretation. *Journal of lower genital tract disease*, 25(2), 172–180. <https://doi.org/10.1097/LGT.0000000000000595>.
6. Verstraelen, Hans MD, MPH, PhD1,2; Vieira-Baptista, Pedro MD3,4,5; De Seta, Francesco MD6,7; Ventolini, Gary MD, FACOG8; Lonnee-Hoffmann, Risa MD, PhD9,10; Lev-Sagie, Ahinoam MD11,12 The Vaginal Microbiome: I. Research Development, Lexicon, Defining “Normal” and the Dynamics Throughout Women's Lives, *Journal of Lower Genital Tract Disease*: January 2022 - Volume 26 - Issue 1 - p 73-78 doi: 10.1097/LGT.0000000000000643
7. Vaginitis in Nonpregnant Patients: ACOG Practice Bulletin, Number 215. (2020). *Obstetrics and gynecology*, 135(1), e1–e17. <https://doi.org/10.1097/AOG.0000000000003604>

Capítulo 12

1. Pineda M, Dr. Figueroa A, Uribarren T, Castañón. Candidosis vaginal, primera parte: revisión de la clínica, epidemiología y situación de México. Rev. Méd. Risaralda 2015; 21 (1): 58-63.
2. Guideline: Vulvovaginal Candidosis (AWMF 015/072), S2k (excluding chronic mucocutaneous candidosis). Mycoses; 2015, 58 (Suppl. 1), 1–15.
3. Foxman B, Muraglia R, Dietz J-P, Sobel JD, Wagner J. Prevalence of recurrent vulvovaginal candidiasis in 5 European countries and the United States: Results from an internet panel survey. J Low Genit Tract Dis. 2013;17:340–5.
4. Duque. Caracterización de la candidiasis vulvovaginal en mujeres de la ciudad de Medellín, Colombia. Publicación Científica En Ciencias Biomédicas - ISSN:1794-2470 VOL.7 No. 12 Julio - Diciembre De 2009: 111- 174
5. Modrzewska B, Kurnatowski P. Selected pathogenic characteristics of fungi from the genus Candida. Ann Parasitol 2013;59:57-66.
6. & Sobel J. Vulvovaginal candidosis. Lancet 2007;369: 1961-71.
7. Rotem, Fishman, Daniel, Koren, Lunenfeld, Levy. Risk of major congenital malformations following first trimester exposure to vaginal azoles used for treating vulvovaginal candidiasis: a population based retrospective cohort study. BJOG. 2018. May 22. doi: 10.1111/1471-0528.15293. [Epub ahead of print].
8. Persistent vulvar pain. Committee Opinion No. 673. American College of Obstetricians and Gynecologists. Obstet Gynecol 2016;128:e78–84.
9. Landers DV, Wiesenfeld HC, Heine RP, Krohn MA, Hiller SL. Predictive value of the clinical diagnosis of lower genital tract infection in women. Am J Obstet Gynecol. 2004;190:1004—10.
10. Miró, Candidiasis Vulvovaginal, Una antigua enfermedad con nuevos desafíos, Rv IberoAmericana de Micología. 2017.

Enfoque sindromático de la enfermedad vulvar

REFERENCIAS BIBLIOGRÁFICAS

11. Sobel, Recurrent vulvovaginal candidiasis. American Journal of Obstetrics & Gynecology. 2016.
12. Workowski, K. A., Bachmann, L. H., Chan, P. A., Johnston, C. M., Muzny, C. A., Park, I., Reno, H., Zenilman, J. M., & Bolan, G. A. (2021). Sexually Transmitted Infections Treatment Guidelines, 2021. MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports, 70(4), 1–187. <https://doi.org/10.15585/mmwr.rr7004a1>
13. Voegeli D. (2020). Intertrigo: causes, prevention and management. *British journal of nursing (Mark Allen Publishing)*, 29(12), S16–S22. <https://doi.org/10.12968/bjon.2020.29.12.S16>.

REFERENCIAS BIBLIOGRÁFICAS

Capítulo 13

1. Workowski, K. A., Bachmann, L. H., Chan, P. A., Johnston, C. M., Muzny, C. A., Park, I., Reno, H., Zenilman, J. M., & Bolan, G. A. (2021). Sexually Transmitted Infections Treatment Guidelines, 2021. MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports, 70(4), 1–187. <https://doi.org/10.15585/mmwr.rr7004a1>.
 2. Jeanne M. Marrazzo. Interpreting the epidemiology and natural history of bacterial vaginosis: Are we still confused? Anaerobe, Aug 2011;17(4): 186-190. doi:10.1016/j.anaerobe.2011.03.016
 3. Hickey RJ, Xia Zhou, Pierson JD, Ravel J, Forney LJ. Understanding vaginal microbiome complexity from an ecological perspective. Review Article. Translational Research, October 2012;160(4):267-282.
 4. Coudray, M. S., & Madhivanan, P. (2020). Bacterial vaginosis-A brief synopsis of the literature. European journal of obstetrics, gynecology, and reproductive biology, 245, 143–148. <https://doi.org/10.1016/j.ejogrb.2019.12.035>.
 5. Subtil D, Brabant G, Tilloy E, et al. Early clindamycin for bacterial
 6. vaginosis in pregnancy (PREMEVA): a multicentre, doubleblind, randomised controlled trial. Lancet 2018;392:2171–9. PMID:30322724 [https://doi.org/10.1016/S0140-6736\(18\)31617-9](https://doi.org/10.1016/S0140-6736(18)31617-9)
 7. Lev-Sagie, A., De Seta, F., Verstraelen, H., Ventolini, G., Lonnee-Hoffmann, R., & Vieira-Baptista, P. (2022). The Vaginal Microbiome: II. Vaginal Dysbiotic Conditions. Journal of lower genital tract disease, 26(1), 79–84. <https://doi.org/10.1097/LGT.0000000000000644>
- Vaginitis in Nonpregnant Patients: ACOG Practice Bulletin, Number 215. (2020). Obstetrics and gynecology, 135(1), e1–e17. <https://doi.org/10.1097/AOG.0000000000003604>

REFERENCIAS BIBLIOGRÁFICAS

Capítulo 14

1. Cibley LJ. Cytolytic vaginosis. *Am J Obstet Gynecol* 1991;165:1245-9.
2. Payne SC, Cromer PR, Stanek MK, Palmer AA: Evidence of African-American women's frustrations with chronic recurrent bacterial vaginosis. *J Am Acad Nurse Pract* 2010; 22: 101–108.
3. Aballéa S, Guelfucci F, Wagner J, Khemiri A, Dietz JP, Sobel J, Toumi M: Subjective health status and health-related quality of life among women with recurrent vulvovaginal candidosis (RVVC) in Europe and the USA. *Health Qual Life Outcomes* 2013; 11: 169.
4. Karasz A, Anderson M: The vaginitis monologues: women's experiences of vaginal complaints in a primary care setting. *Soc Sci Med* 2003; 56: 1013–1021.
5. Cerikcioglu N, Beksac MS: Cytolytic vaginosis: misdiagnosed as candidal vaginitis. *Infect Dis Obstet Gynecol* 2004; 12: 13–16.
6. Batashki I, Markova D, Milchev N: [Frequency of cytolytic vaginosis – examination of 1152 patients]. *Akush Ginekol (Sofia)* 2009; 48: 15–16.
7. Demirezen S: Cytolytic vaginosis: examination of 2947 vaginal smears. *Cent Eur J Public Health* 2003; 11: 23–24.
8. Wathne B, Holst E, Hovelius B, Mårdh PA. Vaginal discharge-comparison of clinical, laboratory and microbiological findings. *Acta Obstet Gynecol Scand* 1994;73(10):802-8.
9. Cerikcioglu N, Beksac MS. Cytolytic vaginosis: misdiagnosed as candidal vaginitis. *Infect Dis Obstet Gynecol* 2004;12(1):13-6
10. Amaral R, Giraldo PC, Gonçalves AK, Junior JE, Santos- Pereira S, Linhares I, et al. Evaluation of hygienic douching on the vaginal microflora of female sex workers. *Int J STD AIDS* 2007;18(11):770-3
11. Shuhua Y. Clinical Significance and Characteristic Clinical Differences of CytolyticVaginosis in Recurrent Vulvovaginitis. *Gynecol Obstet Invest* 2017;82:137–143
12. Hughes VI, Hiller SL. Microbiologic characteristics of lactobacillus products used for colonization of the vagina. *Obstet Gynecol* 1990;75:245 – 8
13. Mardh PA. The vaginal ecosystem. *Am J Obstet Gynecol* 1991;165:1163 – 8

Enfoque sindromático de la enfermedad vulvar

REFERENCIAS BIBLIOGRÁFICAS

14. Sharp HC, Kronh MA, Klebanoff SJ, et al. The relationship of hydrogen peroxide producing lactobacilli vaginosis and genital microflora in pregnant women. *Obstet Gynecol* 1992;79:369 – 7
15. Nomellini RS, Pansani PL, Murta EF: Frequency of cervical intraepithelial neoplasia and infectious agents for vaginitis in menstrual cycle phase. *Eur J Gynaecol Oncol* 2007; 28:389–393.
16. Osset J, García E, Bartolomé RM, Andreu A. Assessment of the capacity of *Lactobacillus* to inhibit the growth of uropathogens and block adhesion to vaginal epithelial cells. *J Infect Dis* 2001;183(3):485-91.
17. Boris S, Barbés C. Role played by lactobacilli in controlling the population of vaginal pathogens. *Microbes Infect* 2000;2(5):543-6.
18. Lepargneur JP, Rosseau V. Protective role of the Doderlëin flora. *J Gynecol Obstet Biol Reprod (Paris)* 2002;31(5):485-94.
19. Suresh A, Rajesh A, Bhat RM, Rai Y: Cytolytic vaginosis: a review. *Indian J Sex Transm Dis* 2009; 30: 48–50.
20. Shopova E, Tiufekchieva E, Karag'ozov I, Koleva V. Cytolytic vaginosis-- clinical and microbiological study. *Akush Ginekol (Sofia)* 2006;45 Suppl 2:12-3
21. Horowitz BA, Mardh PA, Nagy E, Rank EL. Vaginal lactobacillosis. *American Journal of Obstetrics and Gynecology*. 1994;170:857-861.
22. Land MH, Rouster-Stevens K, Woods CR, Cannon ML, Cnota J, Shetty AK. *Lactobacillus* sepsis associated with probiotic therapy. *Pediatrics* 2005;115(1):178-81.
23. Zein EF, Karaa S, Chemaly A, Saidi I, Daou-Chahine W, Rohban R. *Lactobacillus rhamnosus* septicemia in a diabetic associated with probiotic use: a case report. *Ann Biol Clin (Paris)* 2008;66(2):195-8.
24. Protocolo de investigacion, "prevalencia de microorganismos encontrados en pacientes con flujo vaginal en una unidad de patología cervical, Bogotá, Colombia" Sonia Salamanca, Yury Mendieta. Preparacion Magistral Balcream de bicarbonato, laboratorio Galbar SAS. Tel 57 (1) 8630133, 57 3105888997. Liliana Gallego Mendoza, Quimica Farceutica Universidad Nacional de Colombia.
25. Tempera G, Furneri M. Management of Aerobic Vaginitis. *Gynecol Obstet Invest* 2010;70:244–249.

Enfoque sindromático de la enfermedad vulvar

REFERENCIAS BIBLIOGRÁFICAS

Lev-Sagie, A., De Seta, F., Verstraelen, H., Ventolini, G., Lonnee-Hoffmann, R., & Vieira-Baptista, P. (2022). The Vaginal Microbiome: II. Vaginal Dysbiotic Conditions. Journal of lower genital tract diseases

REFERENCIAS BIBLIOGRÁFICAS

Capítulo 15

1. Farinati, Alicia. Flujo Vaginal, vaginitis-vaginosis-cervicitis: abordaje integral del diagnóstico y tratamiento de las infecciones que producen flujo vaginal. 1ª edición ilustrada. Ciudad Autónoma de Buenos Aires: Ascune, 2017. 240 p. ISBN 978-950-9124-66-0.
2. Donders G. Definition and classification of abnormal vaginal flora. *Best Pract Res Clin Obstet Gynaecol.* 2007; 21: 355.
3. Russell N, Seale A, O'Driscoll M, O'Sullivan C, Bianchi-Jassir F, Gonzalez J, Lawn J,
4. Baker C, Bartlett L, Cutland C, Gravett M, Heath P, Doare K, Madhi, Rubens K, Schrag S, Sobanjo-ter Meulen, Vekemans J, Saha S; for the GBS Maternal Colonization Investigator Group. Maternal Colonization With Group B Streptococcus and Serotype Distribution Worldwide: Systematic Review and Meta-analyses. *Clinical Infectious Diseases.* 2017;65 (Suppl 2): 100-111.
5. Tempera G, Furneri M. Management of Aerobic Vaginitis. *Gynecol Obstet Invest* 2010;70:244–249.
6. Heczko P, Tomusiak A, Adamski K, Jakimiuk A, Stefanski G, Mikołajczyk A, Suda-Szczurek M, Strus. Supplementation of standard antibiotic therapy with oral probiotics for bacterial vaginosis and aerobic vaginitis: a randomised, double-blind, placebo-controlled trial. *BMC Women's Health.* 2015; 15: 1-12.
7. Kaambo E, Africa C, Chambuso R, Passmore J. Vaginal Microbiomes Associated With Aerobic Vaginitis and Bacterial Vaginosis. *Frontiers in Public Health.* 2018; 6 (78): 1-6
8. Rumyantseva T, Bellen G, Savochkina Y, Guschin A, Donders G. Diagnosis of aerobic vaginitis by quantitative real-time PCR. *Arch Gynecol Obstet.* 2016; 294:109–114.

REFERENCIAS BIBLIOGRÁFICAS

Capítulo 16

1. Lynch P, Moyal-Barraco M, Scurry J, Stockdale C. 2011 ISSVD Terminology and Classification of Vulvar Dermatological Disorders: An Approach to Clinical Diagnosis. *J Low Genit Tract Dis.* 2012 Oct;16(4):339-44
2. Stewart K. A Clinical Approach to Vulvar Ulcers. *Obstet Gynecol Clin N Am* 44 (2017) 445–451
3. TANJA G. BOHL. Vulvar ulcers and erosions— a dermatologist's viewpoint. *Dermatologic Therapy.* 2004; 17: 55 – 67.
4. Workowski, K. A., Bachmann, L. H., Chan, P. A., Johnston, C. M., Muzny, C. A., Park, I., Reno, H., Zenilman, J. M., & Bolan, G. A. (2021). Sexually Transmitted Infections Treatment Guidelines, 2021. *MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports*, 70(4), 1–187. <https://doi.org/10.15585/mmwr.rr7004a1>.
5. Sadoghi, B., Stary, G., Wolf, P., & Komericki, P. (2019). *Ulcus vulvae acutum Lipschütz (UVAL): a systematic literature review and a diagnostic and therapeutic algorithm. Journal of the European Academy of Dermatology and Venereology.* doi:10.1111/jdv.16161
6. Mauskar M. (2017). Erosive Lichen Planus. *Obstetrics and gynecology clinics of North America*, 44(3), 407–420. <https://doi.org/10.1016/j.ogc.2017.04.004M>
7. ak, S., Logemann, S., Dee, C., & Fershko, A. (2017). Breaking the Magic: Mouth and Genital Ulcers with Inflamed Cartilage Syndrome. *Cureus*, 9(10), e1743. <https://doi.org/10.7759/cureus.1743>
8. Bohl T. Fissures, Herpes Simplex Virus, and Drug Reactions Important Erosive Vulvar Disorders. *Obstet Gynecol Clin N Am.* 2017; 44: 421–443

REFERENCIAS BIBLIOGRÁFICAS

Capítulo 17

1. Rechenchoski DZ, Faccin-Galhardi LC, Linhares REC, Nozawa C. Herpesvirus: an underestimated virus. *Folia Microbiol (Praha)*. 2017;62(2):151-6.
2. Sauerbrei A. Herpes Genitalis: Diagnosis, Treatment and Prevention. *Geburtshilfe Frauenheilkd*. 2016;76(12):1310-7.
3. Sucato G, Wald A, Wakabayashi E, Vieira J, Corey L. Evidence of latency and reactivation of both herpes simplex virus (VHS)-1 and VHS-2 in the genital region. *J Infect Dis*. 1998;177(4):1069-72.
4. Gupta R, Warren T, Wald A. Genital herpes. *The Lancet*. 2007;370(9605):2127-37.
5. Workowski KA, Berman SM. Sexually transmitted diseases treatment guidelines, 2006. *MMWR Recomm Rep*. 2006;55(Rr-11):1-94.
6. Seroprevalence of herpes simplex virus type 2 among persons aged 14-49 years--United States, 2005-2008. *MMWR Morb Mortal Wkly Rep*. 2010;59(15):456-9.
7. Halpern-Felsher BL, Cornell JL, Kropp RY, Tschann JM. Oral versus vaginal sex among adolescents: perceptions, attitudes, and behavior. *Pediatrics*. 2005;115(4):845-51.
8. Mertz GJ, Benedetti J, Ashley R, Selke SA, Corey L. Risk factors for the sexual transmission of genital herpes. *Ann Intern Med*. 1992;116(3):197-202.
9. Cowan FM, French RS, Mayaud P, Gopal R, Robinson NJ, de Oliveira SA, et al. Seroepidemiological study of herpes simplex virus types 1 and 2 in Brazil, Estonia, India, Morocco, and Sri Lanka. *Sex Transm Infect*. 2003;79(4):286-90.
10. Cowan FF, Pascoe SJ, Barlow KL, Langhaug LF, Jaffar S, Hargrove JW, et al. Association of genital shedding of herpes simplex virus type 2 and HIV-1 among sex workers in rural Zimbabwe. *Aids*. 2006;20(2):261-7.
11. Cherpes TL, Melan MA, Kant JA, Cosentino LA, Meyn LA, Hillier SL. Genital tract shedding of herpes simplex virus type 2 in women: effects of hormonal contraception, bacterial vaginosis, and vaginal group B *Streptococcus* colonization. *Clin Infect Dis*. 2005;40(10):1422-8.

Enfoque sindromático de la enfermedad vulvar

REFERENCIAS BIBLIOGRÁFICAS

12. Leone P, Fleming DT, Gilksen AW, Li L, Justus S. Seroprevalence of herpes simplex virus-2 in suburban primary care offices in the United States. *Sex Transm Dis.* 2004;31(5):311-6.
13. Wald A, Zeh J, Selke S, Warren T, Ryncarz AJ, Ashley R, et al. Reactivation of genital herpes simplex virus type 2 infection in asymptomatic seropositive persons. *N Engl J Med.* 2000;342(12):844-50.
14. Patnaik P, Herrero R, Morrow RA, Munoz N, Bosch FX, Bayo S, et al. Type-specific seroprevalence of herpes simplex virus type 2 and associated risk factors in middle-aged women from 6 countries: the IARC multicentric study. *Sex Transm Dis.* 2007;34(12):1019-24.
15. Sierra CA, Bedoya AM, Paris S, Baena A, Gaviria AM, Rojas CA, et al. Prevalence of specific herpes simplex virus-2 antibodies and associated factors in women of a rural town of Colombia. *Trans R Soc Trop Med Hyg.* 2011;105(4):232-8.
16. Kinchington PR, Leger AJ, Guedon JM, Hendricks RL. Herpes simplex virus and varicella zoster virus, the house guests who never leave. *Herpesviridae.* 2012;3(1):5.
17. Sauerbrei A. Optimal management of genital herpes: current perspectives. *Infect Drug Resist.* 2016;9:129-41.
18. Garland SM, Steben M. Genital herpes. *Best Pract Res Clin Obstet Gynaecol.* 2014;28(7):1098-110.
19. Sepulveda-Crespo D, Cena-Diez R, Jimenez JL, Angeles Munoz-Fernandez M. Mechanistic Studies of Viral Entry: An Overview of Dendrimer-Based Microbicides As Entry Inhibitors Against Both HIV and VHS-2 Overlapped Infections. *Med Res Rev.* 2017;37(1):149-79.
20. Gnann JW, Jr., Whitley RJ. CLINICAL PRACTICE. Genital Herpes. *N Engl J Med.* 2016;375(7):666-74.
21. Looker KJ, Garnett GP. A systematic review of the epidemiology and interaction of herpes simplex virus types 1 and 2. *Sex Transm Infect.* 2005;81(2):103-7.

Enfoque sindromático de la enfermedad vulvar

REFERENCIAS BIBLIOGRÁFICAS

22. Langenberg AG, Corey L, Ashley RL, Leong WP, Straus SE. A prospective study of new infections with herpes simplex virus type 1 and type 2. Chiron VHS Vaccine Study Group. *N Engl J Med*. 1999;341(19):1432-8.
23. Roest RW, Carman WF, Maertzdorf J, Scoular A, Harvey J, Kant M, et al. Genotypic analysis of sequential genital herpes simplex virus type 1 (VHS-1) isolates of patients with recurrent VHS-1 associated genital herpes. *J Med Virol*. 2004;73(4):601-4.
24. Schacker T, Zeh J, Hu HL, Hill E, Corey L. Frequency of symptomatic and asymptomatic herpes simplex virus type 2 reactivations among human immunodeficiency virus-infected men. *J Infect Dis*. 1998;178(6):1616-22.
25. Corey L, Adams HG, Brown ZA, Holmes KK. Genital herpes simplex virus infections: clinical manifestations, course, and complications. *Ann Intern Med*. 1983;98(6):958-72.
26. Goodell SE, Quinn TC, Mkrtychian E, Schuffler MD, Holmes KK, Corey L. Herpes simplex virus proctitis in homosexual men. Clinical, sigmoidoscopic, and histopathological features. *N Engl J Med*. 1983;308(15):868-71.
27. Bernstein DI, Lovett MA, Bryson YJ. Serologic analysis of first-episode nonprimary genital herpes simplex virus infection. Presence of type 2 antibody in acute serum samples. *Am J Med*. 1984;77(6):1055-60.
28. Steben M. Genital herpes simplex virus infection. *Clin Obstet Gynecol*. 2005;48(4):838-44.
29. Freeman EE, Weiss HA, Glynn JR, Cross PL, Whitworth JA, Hayes RJ. Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies. *Aids*. 2006;20(1):73-83.
30. Corey L. Synergistic copathogens--HIV-1 and VHS-2. *N Engl J Med*. 356. United States 2007. p. 854-6.
31. Groves MJ. Genital Herpes: A Review. *Am Fam Physician*. 2016;93(11):928-34.
32. Tan DH, Kaul R, Walsmley S. Left out but not forgotten: Should closer attention be paid to coinfection with herpes simplex virus type 1 and HIV? *Can J Infect Dis Med Microbiol*. 2009;20(1):e1-7.

REFERENCIAS BIBLIOGRÁFICAS

33. Dunphy K. Herpes genitalis and the philosopher's stance. *J Med Ethics*. 2014;40(12):793-7.
34. Benedetti J, Corey L, Ashley R. Recurrence rates in genital herpes after symptomatic first-episode infection. *Ann Intern Med*. 1994;121(11):847-54.
35. Lafferty WE, Coombs RW, Benedetti J, Critchlow C, Corey L. Recurrences after oral and genital herpes simplex virus infection. Influence of site of infection and viral type. *N Engl J Med*. 1987;316(23):1444-9.
36. Engelberg R, Carrell D, Krantz E, Corey L, Wald A. Natural history of genital herpes simplex virus type 1 infection. *Sex Transm Dis*. 2003;30(2):174-7.
37. Tronstein E, Johnston C, Huang ML, Selke S, Magaret A, Warren T, et al. Genital shedding of herpes simplex virus among symptomatic and asymptomatic persons with VHS-2 infection. *Jama*. 2011;305(14):1441-9.
38. Schiffer JT, Mayer BT, Fong Y, Swan DA, Wald A. Herpes simplex virus-2 transmission probability estimates based on quantity of viral shedding. *J R Soc Interface*. 2014;11(95):20140160.
39. Sexually transmitted diseases treatment guidelines 2002. Centers for Disease Control and Prevention. *MMWR Recomm Rep*. 2002;51(Rr-6):1-78.
40. Patel R, Kennedy OJ, Clarke E, Geretti A, Nilsen A, Lautenschlager S, et al. 2017 European guidelines for the management of genital herpes. *Int J STD AIDS*. 2017;28(14):1366-79.
41. Ramaswamy M, McDonald C, Smith M, Thomas D, Maxwell S, Tenant-Flowers M, et al. Diagnosis of genital herpes by real time PCR in routine clinical practice. *Sex Transm Infect*. 2004;80(5):406-10.
42. Scoular A, Gillespie G, Carman WF. Polymerase chain reaction for diagnosis of genital herpes in a genitourinary medicine clinic. *Sex Transm Infect*. 2002;78(1):21-5.
43. Sen P, Barton SE. Genital herpes and its management. *Bmj*. 2007;334(7602):1048-52.

Enfoque sindromático de la enfermedad vulvar

REFERENCIAS BIBLIOGRÁFICAS

44. Scheper T, Saschenbrecker S, Steinhagen K, Sauerbrei A, Suer W, Meyer W, et al. The glycoproteins C and G are equivalent target antigens for the determination of herpes simplex virus type 1-specific antibodies. *J Virol Methods*. 2010;166(1-2):42-7.
45. Wald A, Ashley-Morrow R. Serological testing for herpes simplex virus (VHS)-1 and VHS-2 infection. *Clin Infect Dis*. 2002;35(Suppl 2):S173-82.
46. Workowski KA, Bolan GA. Sexually transmitted diseases treatment guidelines, 2015. *MMWR Recomm Rep*. 2015;64(Rr-03):1-137.
47. Krantz I, Lowhagen GB, Ahlberg BM, Nilstun T. Ethics of screening for asymptomatic herpes virus type 2 infection. *Bmj*. 2004;329(7466):618-21.
48. Chernes TL, Meyn LA, Hillier SL. Cunnilingus and vaginal intercourse are risk factors for herpes simplex virus type 1 acquisition in women. *Sex Transm Dis*. 2005;32(2):84-9.
49. Link BG, Phelan JC. Stigma and its public health implications. *Lancet*. 2006;367(9509):528-9.
50. Corey L, Holmes KK. Genital herpes simplex virus infections: current concepts in diagnosis, therapy, and prevention. *Ann Intern Med*. 1983;98(6):973-83.
51. Beaman JG. Genital herpes: a review. *Am Fam Physician*. 2005;72(8):1527-34.
52. Lebrun-Vignes B, Bouzamondo A, Dupuy A, Guillaume JC, Lechat P, Chosidow O. A meta-analysis to assess the efficacy of oral antiviral treatment to prevent genital herpes outbreaks. *J Am Acad Dermatol*. 2007;57(2):238-46.
53. Mertz GJ, Jones CC, Mills J, Fife KH, Lemon SM, Stapleton JT, et al. Long-term acyclovir suppression of frequently recurring genital herpes simplex virus infection. A multicenter double-blind trial. *Jama*. 1988;260(2):201-6.
54. Strick LB, Wald A, Celum C. Management of herpes simplex virus type 2 infection in HIV type 1-infected persons. *Clin Infect Dis*. 2006;43(3):347-56.
55. Corey L, Nahmias AJ, Guinan ME, Benedetti JK, Critchlow CW, Holmes KK. A trial of topical acyclovir in genital herpes simplex virus infections. *N Engl J Med*. 1982;306(22):1313-9.

Enfoque sindromático de la enfermedad vulvar

REFERENCIAS BIBLIOGRÁFICAS

56. Griffith RS, Walsh DE, Myrmel KH, Thompson RW, Behforooz A. Success of L-lysine therapy in frequently recurrent herpes simplex infection. Treatment and prophylaxis. *Dermatologica*. 1987;175(4):183-90.
57. Csonka GW, Tyrrell DA. Treatment of herpes genitalis with carbenoxolone and cicloxolone creams: a double blind placebo controlled clinical trial. *Br J Vener Dis*. 1984;60(3):178-81.
58. Wolbling RH, Leonhardt K. Local therapy of herpes simplex with dried extract from *Melissa officinalis*. *Phytomedicine*. 1994;1(1):25-31.
59. Syed T, Afzal M, Ahmad SA, Holt A, Ahmad SA, Ahmad S. Management of genital herpes in men with 0.5% Aloe vera extract in a hydrophilic cream: a placebo-controlled double-blind study. *Journal of Dermatological Treatment*. 1997;8(2):99-102.
60. Stanberry LR, Cunningham AL, Mindel A, Scott LL, Spruance SL, Aoki FY, et al. Prospects for control of herpes simplex virus disease through immunization. *Clin Infect Dis*. 2000;30(3):549-66.
61. Spruance SL, Tyring SK, Smith MH, Meng TC. Application of a topical immune response modifier, resiquimod gel, to modify the recurrence rate of recurrent genital herpes: a pilot study. *J Infect Dis*. 2001;184(2):196-200.
62. Corey L, Wald A. Maternal and neonatal herpes simplex virus infections. *N Engl J Med*. 2009;361(14):1376-85.
63. Straface G, Selmin A, Zanardo V, De Santis M, Ercoli A, Scambia G. Herpes simplex virus infection in pregnancy. *Infect Dis Obstet Gynecol*. 2012;2012:385697.
64. Brown ZA, Selke S, Zeh J, Kopelman J, Maslow A, Ashley RL, et al. The acquisition of herpes simplex virus during pregnancy. *N Engl J Med*. 1997;337(8):509-15.
65. Sauerbrei A, Wutzler P. Herpes simplex and varicella-zoster virus infections during pregnancy: current concepts of prevention, diagnosis and therapy. Part 1: herpes simplex virus infections. *Med Microbiol Immunol*. 2007;196(2):89-94.
66. Brown ZA, Gardella C, Wald A, Morrow RA, Corey L. Genital herpes complicating pregnancy. *Obstet Gynecol*. 2005;106(4):845-56.

Enfoque sindromático de la enfermedad vulvar

REFERENCIAS BIBLIOGRÁFICAS

67. Brown ZA, Wald A, Morrow RA, Selke S, Zeh J, Corey L. Effect of serologic status and cesarean delivery on transmission rates of herpes simplex virus from mother to infant. *Jama*. 2003;289(2):203-9.
68. Westhoff GL, Little SE, Caughey AB. Herpes simplex virus and pregnancy: a review of the management of antenatal and peripartum herpes infections. *Obstet Gynecol Surv*. 2011;66(10):629-38.
69. Pasternak B, Hviid A. Use of acyclovir, valacyclovir, and famciclovir in the first trimester of pregnancy and the risk of birth defects. *Jama*. 2010;304(8):859-66.
70. Stephenson-Famy A, Gardella C. Herpes simplex virus infection during pregnancy. *Obstet Gynecol Clin North Am*. 2014;41(4):601-14.
71. Watts DH, Brown ZA, Money D, Selke S, Huang ML, Sacks SL, et al. A double-blind, randomized, placebo-controlled trial of acyclovir in late pregnancy for the reduction of herpes simplex virus shedding and cesarean delivery. *Am J Obstet Gynecol*. 2003;188(3):836-43.

REFERENCIAS BIBLIOGRÁFICAS

Capítulo 18

1. Aruna Venkatesan, Pigmented Lesions of the Vulva Dermatologic Clinics, Volume 28, Issue 4, 2010, Pages 795-805
2. Era Caterina Murzaku, Lauren A. Penn, Christopher S. Hale, Miriam Keltz Pomeranz, David Polsky, Vulvar nevi, melanosis, and melanoma: An epidemiologic, clinical, and histopathologic review, Journal of the American Academy of Dermatology, Volume 71, Issue 6, 2014, Pages 1241-1249 .
3. Jill I. Allbritton, Vulvar Neoplasms, Benign and Malignant, Obstetrics and Gynecology Clinics of North America, Volume 44, Issue 3, 2017, Pages 339-352.
4. Freja Lærke Sand1 and Simon Francis Thomsen Clinician's Update on the Benign, Premalignant, and Malignant Skin Tumours of the Vulva: The Dermatologist's View International Scholarly Research Notices Volume 2017, Article ID 2414569, 10 pages
5. Charles J.N. Lacey, Genital warts and mucosal papillomavirus disease, Medicine, Volume 42, Issue 7, 2014, Pages 349-353
6. Alexandra M. Haugh, Emily A. Merkel, Bin Zhang, Jeffrey A. Bubley, Anna Elisa Verzì, Christina Y. Lee, Pedram Gerami, A clinical, histologic, and follow-up study of genital melanosis in men and women, Journal of the American Academy of Dermatology, Volume 76, Issue 5, 2017, Pages 836-840,
7. . P. Lenane, C.O. Keane, B.O. Connell, S.O. Loughlin, F.C. Powell, Genital melanotic macules: Clinical, histologic, immunohistochemical, and ultrastructural features, Journal of the American Academy of Dermatology, Volume 42, Issue 4, 2000, Pages 640-644

REFERENCIAS BIBLIOGRÁFICAS

Capítulo 19

1. C. Ahn, A. Guerra, O. Saguenza . Melanocytic nevi of Special Sites. Am Journal of Dermatopathology 2016; 38:867-881
2. Ribé A. Melanocytic lesions of the genital area with attention given to atypical genital nevi. J Cutan Pathol. 2008 Nov;35 Suppl 2:24-7.
3. Edwards L. Pigmented vulvar lesions. Dermatologic Therapy, vol 23, 2010, 449-457.
4. T Brenn. Atypical Genital Nevus. Arch Pathol Lab Med. 2011; 135: 317-320
C. Murzaku, L. Penn, C Hale. Vulvar nevi, melanosis and melanoma: An epidemiological, clinical and histopathologic review. Journal of American Academy of Dermatology 2014; 71:1241-4
5. Venkatesan A. Pigmented lesions of the vulva. Dermatol Clin. 2010;28(4):795-805
6. Krathen MS, Liu CL, Loo DS. Vulvar melanoma: a missed opportunity for early intervention? J Am Acad Dermatol. 66. United States 2012. p. 697-8
7. Murzaku EC, Penn LA, Hale CS, Pomeranz MK, Polsky D. Vulvar nevi, melanosis, and melanoma: an epidemiologic, clinical, and histopathologic review. J Am Acad Dermatol. 2014;71(6):1241-9
8. Jaimes N, Halpern AC. Practice Gaps. Examination of genital area: comment on "Dermoscopy of pigmented lesions of the mucosa and the mucocutaneous junction". Arch Dermatol. 2011;147(10):1187-8.
9. Ferrari A, Buccini P, Covello R, De Simone P, Silipo V, Mariani G, et al. The ringlike pattern in vulvar melanosis: a new dermoscopic clue for diagnosis. Arch Dermatol. 2008;144(8):1030-4.
10. Blum A, Simionescu O, Argenziano G, Braun R, Cabo H, Eichhorn A, et al. Dermoscopy of pigmented lesions of the mucosa and the mucocutaneous junction: results of a multicenter study by the International Dermoscopy Society (IDS). Arch Dermatol. 2011;147(10):1181-7.
11. Ronger-Savle S, Julien V, Duru G, Raudrant D, Dalle S, Thomas L. Features of pigmented vulval lesions on dermoscopy. Br J Dermatol. 2011;164(1):54-61.
12. Cengiz FP, Emiroglu N, Wellenhof RH. Dermoscopic and clinical features of pigmented skin lesions of the genital area. An Bras Dermatol. 2015;90(2):178-83.

Enfoque sindromático de la enfermedad vulvar

REFERENCIAS BIBLIOGRÁFICAS

REFERENCIAS BIBLIOGRÁFICAS

Capítulo 20

1. Sand FL, Thomsen SE. Clinician's Update on the Benign, Premalignant, and Malignant Skin Tumours of the Vulva: The Dermatologist's View. *Int Sch Res Not*. 2017;1-10.
2. Anderson SR. Benign vulvovaginal cysts. *Diagnostic Histopathol*. 2017;23:14-8.
3. Karaman E, Cim N, Akdemir Z, Elci E, Akdeniz H. Giant vulvar epidermoid cyst in an adolescent girl. *Case Rep Obstet Gynecol*. 2015;1-3.
4. Di Gregorio M, Lorge F, Dupont M. Female Urethral Diverticulum: Diagnosis, Treatment and Outcome. *Gynecol Obstet*. 2015;6:4-8.
5. Bernal Martínez, S. Olivares Valencia, C. Ayala Castellanos, M. Cerda Camacho F. Polipo Fibroepitelial De La Vulva (Acrocordon) Presentacion De Un Caso Y Revision De La Literatura. *Medigraphic*. 2011;5-8.
6. Ruiz-Villaverde R, Martinez-Lopez A, Durá EG. Queratosis seborreica vulvar: imitadora de melanoma. *Piel*. 2017;32:526-8.
7. Maldonado VA. Benign vulvar tumors. *Best Pract Res Clin Obstet Gynaecol*. 2014;28:1088-97.
8. Agudelo, C. Pareja, L. Rendón, G. Serna C. Queratoacantoma de vulva: presentación de un caso. *Rev Chil Obs Ginecol*. 2015;80:401-4.
9. Gurusamy L, Jegadeesan M, Jayakumar S. Fox – Fordyce disease of the vulva Full Text Introduction Case Report. 2016;14:2016-8.
10. Pardo-Zamudio C, Plaza-Arteaga N. Papilomatosis vestibular: Variante anatómica de la vulva. *Piel*. 2017;9-11.
11. Kurashige Y, Kishida K, Kurashige K, Minemura T, Nagatani T. Hidradenoma papilliferum of the vulva in association with an anogenital mammary-like gland. *J Dermatol*. 2014;41:411-3.
12. Cheng Flores, I. Gutiérrez Oliveros, T. González Cabello D. Siringomas en la vulva. *Dermatologia Rev Mex*. 2011;55:152-4.

Enfoque sindromático de la enfermedad vulvar

REFERENCIAS BIBLIOGRÁFICAS

13. Kurtoğlu E. Nodular Hyperplasia of the Bartholins Glands. *J Clin Anal Med*. 2015;6:219-21.
14. Denlinger LN, Lokhandwala PM, Abendroth CS. Benign phyllodes tumor of the vulva: A case report and literature review. *Rare Tumors*. 2015;7:148-50.
15. Kazakow D, Michal M, Kacerovska D MP. Cutaneous adnexal Tumor. 1.^a ed. Wolters Kluwer Health, editor. 2012. 453-497.
16. Jimenez GA VA. Fibroadenoma vulvar : reporte de un caso y revisión de la literatura. *MEDUIS*. 2014;27:93-6.
17. Braudis K, Pincus LB. Cutaneous Adnexal Tumors. First Edit. Wolters Kluwer Health, editor. Lippincott Williams & Wilkins. Philadelphia: 2012; 2012. 680-684.
18. Konstantinova AM, Kyrpychova L, Belousova IE, Spagnolo D V., Kacerovska D, Michal M, et al. Anogenital Mammary-Like Glands: A Study of Their Normal Histology with Emphasis on Glandular Depth, Presence of Columnar Epithelial Cells, and Distribution of Elastic Fibers. *Am J Dermatopathol*. 2017;39:663-7.
19. Scurry J, Van Der Putte SCJ, Pyman J, Chetty N, Szabo R. Mammary-like gland adenoma of the vulva: Review of 46 cases. *Pathology*. 2009;41:372-8.
20. Requena L SO. Cutaneous Adnexal Neoplasms. 1.^a ed. Springer, editor. Swizerland; 2017. 225-230 p.
21. Bedoya R. Enfermedad de Paget de la vulva : estudio inmunohistoquímico. *Rev Med Costa Rica*. 2015;29:355-9.
22. Baker GM, Selim MA, Hoang MP. Vulvar adnexal lesions: a 32-year, single-institution review from Massachusetts General Hospital. *Arch Pathol Lab Med*. 2013;137:1237-46.
23. McCluggage WG, Ganesan R, Hirschowitz L, Rollason TP. Cellular angiofibroma and related fibromatous lesions of the vulva: Report of a series of cases with a morphological spectrum wider than previously described. *Histopathology*. 2004;45:360-8.
24. Guzmán Muñoz M, Delgado JJ, Ramos P, Heron S, Martínez-Parrondo N, Cano A, et al. Angiofibroma celular de vulva: Una entidad a investigar. *Clin Invest Ginecol Obstet*.

Enfoque sindromático de la enfermedad vulvar

REFERENCIAS BIBLIOGRÁFICAS

- 2012;39:265-7.
25. Wani Y FY. A vulvar fibroepithelial stromal polyp appearing in infancy. *Am J Dermatopathol*. 2009;33:465-7.
 26. Schoolmeester JK, Fritchie KJ. Genital soft tissue tumors. *J Cutan Pathol*. 2015;42:441-51.
 27. Odoi AT, Owusu-Bempah A, Dassah ET, Darkey DE, Quayson SE. Case Reports Vulvar Lipoma : Is It So Rare ? *Ghana Med J*. 2011;45:125-7.
 28. Jayi S, Laadioui M, El Fatemi H, Fdili FZ, Bouguern H, Chaara H, et al. Vulvar lipoma: A case report. *J Med Case Rep*. 2014;8(1):2-4.
 29. Balci O, Ercan F, Salim G. Lymphangioma circumscriptum of the vulva: A rare case report. *Clin Exp Obstet Gynecol*. 2017;44:936-8.
 30. Nasu K, Okamoto M, Nishida M, Narahara H. Endometriosis of the perineum. *J Obs Gynaecol Res*. 2013;39:1095-7.
 31. Li J, Shi Y, Zhou C, Lin J. Diagnosis and treatment of perineal endometriosis: review of 17 cases. *Arch Gynecol Obs*. 2015;292:1295-9.

REFERENCIAS BIBLIOGRÁFICAS

Capítulo 21

1. <https://www.cdc.gov/spanish/cancer/vagvulv/statistics/>. Consultado: Mayo 2017.
2. Bornstein J1, Bogliatto F, Haefner HK, Stockdale CK, Preti M, Bohl TG, Reutter J; ISSVD Terminology Committee. The 2015 International Society for the Study of Vulvovaginal Disease (ISSVD) Terminology of Vulvar Squamous Intraepithelial Lesions. *Obstet Gynecol*. 2016 Feb;127(2):264-8.
3. de Sanjosé S¹, Alemany L, Ordi J, Tous S, Alejo M, Bigby SM, Joura EA, Maldonado P, Laco J, Bravo IG, Vidal A, Guimerà N, Cross P, Wain GV, Petry KU, Mariani L, Bergeron C, Mandys V, Sica AR, Félix A, Usubutun A, Seoud M, Hernández-Suárez G, Nowakowski AM, Wilson G, Dalstein V, Hampl M, Kasamatsu ES, Lombardi LE, Tinoco L, Alvarado-Cabrero I, Perrotta M, Bhatla N, Agorastos T, Lynch CE, Goodman MT, Shin HR, Viarheichyk H, Jach R, Cruz MO, Velasco J, Molina C, Bornstein J, Ferrera A, Domingo EJ, Chou CY, Banjo AF, Castellsagué X, Pawlita M, Lloveras B, Quint WG, Muñoz N, Bosch FX; HPV VVAP study group. Worldwide human papillomavirus genotype attribution in over 2000 cases of intraepithelial and invasive lesions of the vulva. *Eur J Cancer*. 2013 Nov;49(16):3450-6.
4. Louise A. Brinton. Epidemiology of vulvar neoplasia in the NIH-AARP Study.
2. *Gynecologic Oncology*. 2017; 145: 298–304
1. Lynch et al. 2011 ISSVD Terminology and Classification of Vulvar Dermatological Disorders: An Approach to Clinical Diagnosis. *Journal of Lower Genital Tract Disease*, Volume 16, Number 4, 2012, 00Y00
2. Management of vulvar intraepithelial neoplasia. Committee Opinion No. 675. American College of Obstetricians and Gynecologists. *Obstet Gynecol* 2016;128:e178–82.

REFERENCIAS BIBLIOGRÁFICAS

Capítulo 22

1. Schuurman MS, van den Einden LC, Massuger LF, et al. Trends in incidence and survival of Dutch women with vulvar squamous cell carcinoma. *Eur J Cancer* 2013; 49:3872.
2. Saraiya M, Watson M, Wu X, et al. Incidence of in situ and invasive vulvar cancer in the US, 1998-2003. *Cancer* 2008; 113:2865.
3. Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. *CA Cancer J Clin* 2017; 67:7.
4. <https://seer.cancer.gov/statfacts/html/vulva.html> (Accessed on April 28, 2017).
5. de Koning MN, Quint WG, Pirog EC. Prevalence of mucosal and cutaneous human papillomaviruses in different histologic subtypes of vulvar carcinoma. *Mod Pathol* 2008; 21:334.
6. Weberpals JI, Lo B, Duciaume MM, et al. Vulvar Squamous Cell Carcinoma (VSCC) as Two Diseases: HPV Status Identifies Distinct Mutational Profiles Including Oncogenic Fibroblast Growth Factor Receptor 3. *Clin Cancer Res* 2017; 23:4501.
8. van de Nieuwenhof HP, Bulten J, Hollema H, et al. Differentiated vulvar intraepithelial neoplasia is often found in lesions, previously diagnosed as lichen sclerosus, which have progressed to vulvar squamous cell carcinoma. *Mod Pathol* 2011; 24:297.
9. Bigby SM, Eva LJ, Fong KL, Jones RW. The Natural History of Vulvar Intraepithelial Neoplasia, Differentiated Type: Evidence for Progression and Diagnostic Challenges. *Int J Gynecol Pathol* 2016; 35:574.
10. Hørding U, Junge J, Poulsen H, Lundvall F. Vulvar intraepithelial neoplasia III: a viral disease of undetermined progressive potential. *Gynecol Oncol* 1995; 56:276.
11. Srodon M, Stoler MH, Baber GB, Kurman RJ. The distribution of low and high-risk HPV types in vulvar and vaginal intraepithelial neoplasia (VIN and VaIN). *Am J Surg Pathol* 2006; 30:1513.
12. Neill SM, Lewis FM, Tatnall FM, et al. British Association of Dermatologists' guidelines for the management of lichen sclerosus 2010. *Br J Dermatol* 2010; 163:672.

Enfoque sindromático de la enfermedad vulvar

REFERENCIAS BIBLIOGRÁFICAS

13. Modesitt SC, Waters AB, Walton L, et al. Vulvar intraepithelial neoplasia III: occult cancer and the impact of margin status on recurrence. *Obstet Gynecol* 1998; 92:962.
14. Conley LJ, Ellerbrock TV, Bush TJ, et al. HIV-1 infection and risk of vulvovaginal and perianal condylomata acuminata and intraepithelial neoplasia: a prospective cohort study. *Lancet* 2002; 359:108.
15. Hillemanns P, Wang X. Integration of HPV – 16 and HPV- 18 DNA in vulvar intraepithelial neoplasia. *Gynecology Oncology* 2006; 100:276-282.
16. Hildesheim A, Han CL, Brinton LA, et al. Human papillomavirus type 16 and risk of preinvasive and invasive vulvar cancer: results from a seroepidemiological case-control study. *Obstet Gynecol* 1997; 90:748.
17. Iwasawa A, Nieminen P, Lehtinen M, Paavonen J. Human papillomavirus in squamous cell carcinoma of the vulva by polymerase chain reaction. *Obstet Gynecol* 1997; 89:81.
18. Al-Ghamdi A, Freedman D, Miller D, et al. Vulvar squamous cell carcinoma in young women: a clinicopathologic study of 21 cases. *Gynecol Oncol* 2002; 84:94.
19. Elit L, Voruganti S, Simunovic M. Invasive vulvar cancer in a woman with human immunodeficiency virus: case report and review of the literature. *Gynecol Oncol* 2005; 98:151.
20. de Giorgi V, Salvini C, Massi D, et al. Vulvar basal cell carcinoma: retrospective study and review of literature. *Gynecol Oncol* 2005; 97:192.
21. Piura B, Rabinovich A, Dgani R. Basal cell carcinoma of the vulva. *J Surg Oncol* 1999; 70:172.
22. Benedet JL, Miller DM, Ehlen TG, Bertrand MA. Basal cell carcinoma of the vulva: clinical features and treatment results in 28 patients. *Obstet Gynecol* 1997; 90:765.
23. Piura B, Egan M, Lopes A, Monaghan JM. Malignant melanoma of the vulva: a clinicopathologic study of 18 cases. *J Surg Oncol* 1992; 50:234.
24. Stang A, Streller B, Eisinger B, Jöckel KH. Population-based incidence rates of malignant melanoma of the vulva in Germany. *Gynecol Oncol* 2005; 96:216.

Enfoque sindromático de la enfermedad vulvar

REFERENCIAS BIBLIOGRÁFICAS

25. Chang AE, Karnell LH, Menck HR. The National Cancer Data Base report on cutaneous and noncutaneous melanoma: a summary of 84,836 cases from the past decade. The American College of Surgeons Commission on Cancer and the American Cancer Society. *Cancer* 1998; 83:1664.
26. Sugiyama VE, Chan JK, Shin JY, et al. Vulvar melanoma: a multivariable analysis of 644 patients. *Obstet Gynecol* 2007; 110:296.
27. Han CH, Li X, Khanna N. Epithelioid sarcoma of the vulva and its clinical implication: A case report and review of the literature. *Gynecol Oncol Rep* 2016; 15:31.
28. Parker LP, Parker JR, Bodurka-Bervers D, et al. Paget's disease of the vulva: pathology, pattern of involvement, and prognosis. *Gynecol Oncol* 2000; 77:183.
29. DePasquale SE, McGuinness TB, Mangan CE, et al. Adenoid cystic carcinoma of Bartholin's gland: a review of the literature and report of a patient. *Gynecol Oncol* 1996; 61:122.
30. Visco AG, Del Priore G. Postmenopausal bartholin gland enlargement: a hospital-based cancer risk assessment. *Obstet Gynecol* 1996; 87:286.
31. Felix JC, Cote RJ, Kramer EE, et al. Carcinomas of Bartholin's gland. Histogenesis and the etiological role of human papillomavirus. *Am J Pathol* 1993; 142:925.
32. Copeland LJ, Sneige N, Gershenson DM, et al. Bartholin gland carcinoma. *Obstet Gynecol* 1986; 67:794.
33. Rob L, Robova H, Pluta M, et al. Further data on sentinel lymph node mapping in vulvar cancer by blue dye and radiocolloid Tc99. *Int J Gynecol Cancer* 2007; 17:147.
34. Hacker NF, Berek JS, Lagasse LD, et al. Management of regional lymph nodes and their prognostic influence in vulvar cancer. *Obstet Gynecol* 1983; 61:408.
35. Zacur H, Genadry R, Woodruff JD. The patient-at-risk for development of vulvar cancer. *Gynecol Oncol* 1980; 9:199.
36. Collins CG, Lee FY, Roman-Lopez JJ. Invasive carcinoma of the vulva with lymph node metastasis. *Am J Obstet Gynecol* 1971; 109:446.

Enfoque sindromático de la enfermedad vulvar

REFERENCIAS BIBLIOGRÁFICAS

37. Pecorelli S. Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. *Int J Gynaecol Obstet* 2009; 105:103.
38. Hacker NF, Barlow EL. Staging for vulvar cancer. *Best Pract Res Clin Obstet Gynaecol* 2015; 29:802.
39. Gibb RK, Olawaiye AB, Chen LM, et al. Vulva. In: *AJCC Cancer Staging Manual*, 8th ed, Amin MB (Ed), AJCC, Chicago 2017. p.633.
40. Kataoka MY, Sala E, Baldwin P, et al. The accuracy of magnetic resonance imaging in staging of vulvar cancer: a retrospective multi-centre study. *Gynecol Oncol* 2010; 117:82.
41. Cohn DE, Dehdashti F, Gibb RK, et al. Prospective evaluation of positron emission tomography for the detection of groin node metastases from vulvar cancer. *Gynecol Oncol* 2002; 85:179.
42. Lin G, Chen CY, Liu FY, et al. Computed tomography, magnetic resonance imaging and FDG positron emission tomography in the management of vulvar malignancies. *Eur Radiol* 2015; 25:1267.
43. Greer BE, Koh WJ. New NCCN Guidelines for Vulvar Cancer. *J Natl Compr Canc Netw* 2016; 14:656.
44. Heaps JM, Fu YS, Montz FJ, et al. Surgical-pathologic variables predictive of local recurrence in squamous cell carcinoma of the vulva. *Gynecol Oncol* 1990; 38:309.
45. Andersen BL, Hacker NF. Psychosexual adjustment after vulvar surgery. *Obstet Gynecol* 1983; 62:457.
46. DiSaia PJ, Creasman WT, Rich WM. An alternate approach to early cancer of the vulva. *Am J Obstet Gynecol* 1979; 133:825.
47. Podratz KC, Symmonds RE, Taylor WF, Williams TJ. Carcinoma of the vulva: analysis of treatment and survival. *Obstet Gynecol* 1983; 61:63.
48. Balat O, Edwards C, Delclos L. Complications following combined surgery (radical vulvectomy versus wide local excision) and radiotherapy for the treatment of carcinoma of the vulva: report of 73 patients. *Eur J Gynaecol Oncol* 2000; 21:501.

Enfoque sindromático de la enfermedad vulvar

REFERENCIAS BIBLIOGRÁFICAS

49. Ansink A, van der Velden J. Surgical interventions for early squamous cell carcinoma of the vulva. *Cochrane Database Syst Rev* 2000; :CD002036.
50. DeSimone CP, Van Ness JS, Cooper AL, et al. The treatment of lateral T1 and T2 squamous cell carcinomas of the vulva confined to the labium majus or minus. *Gynecol Oncol* 2007; 104:390.
51. Gonzalez Bosquet J, Kinney WK, Russell AH, et al. Risk of occult inguino-femoral lymph node metastasis from squamous carcinoma of the vulva. *Int J Radiat Oncol Biol Phys* 2003; 57:419.
52. Rouzier R, Haddad B, Dubernard G, et al. Inguino-femoral dissection for carcinoma of the vulva: effect of modifications of extent and technique on morbidity and survival. *J Am Coll Surg* 2003; 196:442.
53. Levenback C, Coleman RL, Burke TW, et al. Intraoperative lymphatic mapping and sentinel node identification with blue dye in patients with vulvar cancer. *Gynecol Oncol* 2001; 83:276.
54. Stehman FB, Bundy BN, Dvoretzky PM, Creasman WT. Early stage I carcinoma of the vulva treated with ipsilateral superficial inguinal lymphadenectomy and modified radical hemivulvectomy: a prospective study of the Gynecologic Oncology Group. *Obstet Gynecol* 1992; 79:490.
55. Homesley HD, Bundy BN, Sedlis A, et al. Prognostic factors for groin node metastasis in squamous cell carcinoma of the vulva (a Gynecologic Oncology Group study). *Gynecol Oncol* 1993; 49:279.
56. Gaarenstroom KN, Kenter GG, Trimbos JB, et al. Postoperative complications after vulvectomy and inguino-femoral lymphadenectomy using separate groin incisions. *Int J Gynecol Cancer* 2003; 13:522.
57. Gould N, Kamelle S, Tillmanns T, et al. Predictors of complications after inguinal lymphadenectomy. *Gynecol Oncol* 2001; 82:329.
58. van der Velden J, Fons G, Lawrie TA. Primary groin irradiation versus primary groin surgery for early vulvar cancer. *Cochrane Database Syst Rev* 2011; :CD002224.

Enfoque sindromático de la enfermedad vulvar

REFERENCIAS BIBLIOGRÁFICAS

59. Stehman FB, Bundy BN, Thomas G, et al. Groin dissection versus groin radiation in carcinoma of the vulva: a Gynecologic Oncology Group study. *Int J Radiat Oncol Biol Phys* 1992; 24:389.
60. Gill BS, Bernard ME, Lin JF, et al. Impact of adjuvant chemotherapy with radiation for node-positive vulvar cancer: A National Cancer Data Base (NCDB) analysis. *Gynecol Oncol* 2015; 137:365.
61. Gonzalez Bosquet J, Magrina JF, Gaffey TA, et al. Long-term survival and disease recurrence in patients with primary squamous cell carcinoma of the vulva. *Gynecol Oncol* 2005; 97:828.
62. Beller U, Sideri M, Maisonneuve P, et al. Carcinoma of the vulva. *J Epidemiol Biostat* 2001; 6:155.
63. Salani R, Backes FJ, Fung MF, et al. Posttreatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncologists recommendations. *Am J Obstet Gynecol* 2011; 204:466.
64. Andreasson B, Moth I, Jensen SB, Bock JE. Sexual function and somatopsychic reactions in vulvectomy-operated women and their partners. *Acta Obstet Gynecol Scand* 1986; 65:7.
65. Green MS, Naumann RW, Elliot M, et al. Sexual dysfunction following vulvectomy. *Gynecol Oncol* 2000; 77:73.
66. Maggino T, Landoni F, Sartori E, et al. Patterns of recurrence in patients with squamous cell carcinoma of the vulva. A multicenter CTF Study. *Cancer* 2000; 89:116.
67. Burger MP, Hollema H, Emanuels AG, et al. The importance of the groin node status for the survival of T1 and T2 vulval carcinoma patients. *Gynecol Oncol* 1995; 57:327.
68. Gadducci A, Cionini L, Romanini A, et al. Old and new perspectives in the management of high-risk, locally advanced or recurrent, and metastatic vulvar cancer. *Crit Rev Oncol Hematol* 2006; 60:227.
69. De Hullu JA, Hollema H, Lolkema S, et al. Vulvar carcinoma. The price of less radical surgery. *Cancer* 2002; 95:2331.

Enfoque sindromático de la enfermedad vulvar

REFERENCIAS BIBLIOGRÁFICAS

70. Woolderink JM, de Bock GH, de Hullu JA, et al. Patterns and frequency of recurrences of squamous cell carcinoma of the vulva. *Gynecol Oncol* 2006; 103:293.
71. Beller U, Quinn MA, Benedet JL, et al. Carcinoma of the vulva. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. *Int J Gynaecol Obstet* 2006; 95 Suppl 1:S7.
72. Homesley HD, Bundy BN, Sedlis A, et al. Assessment of current International Federation of Gynecology and Obstetrics staging of vulvar carcinoma relative to prognostic factors for survival (a Gynecologic Oncology Group study). *Am J Obstet Gynecol* 1991; 164:997.
73. Landrum LM, Lanneau GS, Skaggs VJ, et al. Gynecologic Oncology Group risk groups for vulvar carcinoma: improvement in survival in the modern era. *Gynecol Oncol* 2007; 106:521.

REFERENCIAS BIBLIOGRÁFICAS

Capítulo 23

1. Sociedade Galega da dor e cuidados paliativos (2017). Manual básico de dolor de la SGADOR. Edición Enfoque Editorial SC.
2. Khoder W, Hale D. Pudendal neuralgia. *Obstet Gynecol Clin North Am.* 2014 Sep;41(3):443-52. doi: 10.1016/j.ogc.2014.04.002. Epub 2014 Jul 9. PMID: 25155124.
3. Haefner H. Vulvar Anatomy. 3rd ed. *Obstetric and Gynecologic Dermatology.* Mosby; 2008.
4. Netter F. *Atlas of Human Anatomy.* 6th ed. Elsevier; 2014.
5. Latarjet M, Ruiz L. *Anatomía humana.* 5th ed. Panamericana
6. Fatton B, Cayrac M, Letouzey V, Masia F, Mousty E, Mares P, Prudhomme M, Tayrac de R. *Anatomía funcional del piso pélvico.* EMC - Ginecología - Obstetricia. 2015; 51(1): 1-4.
7. Descouvieres C. Piso Pélvico Femenino, *Revista Chilena de Urología.* 2015; 80(2):11-17.
8. Torres-Cueco, R., & Nohales-Alfonso, F. (2021). Vulvodynia-It Is Time to Accept a New Understanding from a Neurobiological Perspective. *International journal of environmental research and public health*, 18(12), 6639. <https://doi.org/10.3390/ijerph18126639>

REFERENCIAS BIBLIOGRÁFICAS

Capítulo 24

1. Bergeron S, Reed BD, Wesselmann U, Bohm-Starke N. Vulvodynia. *Nat Rev Dis Primers*. 2020 Apr 30;6(1):36. doi: 10.1038/s41572-020-0164-2. PMID: 32355269
2. Edwards L. Vulvodynia. *Clin Obstet Gynecol*. 2015 Mar;58(1):143-52. doi: 10.1097/GRF.0000000000000093. PMID: 25608256.
3. Khoder W, Hale D. Pudendal neuralgia. *Obstet Gynecol Clin North Am*. 2014 Sep;41(3):443-52. doi: 10.1016/j.ogc.2014.04.002. Epub 2014 Jul 9. PMID: 25155124.
4. Haefner H. Vulvar Anatomy. 3rd ed. *Obstetric and Gynecologic Dermatology*. Mosby; 2008.
5. Netter F. *Atlas of Human Anatomy*. 6th ed. Elsevier; 2014.
6. Latarjet M, Ruiz L. *Anatomía humana*. 5th ed. Panamericana.
7. Fatton B, Cayrac M, Letouzey V, Masia F, Mousty E, Mares P, Prudhomme M, Tayrac de R. Anatomía funcional del piso pélvico. *EMC - Ginecología - Obstetricia*. 2015; 51(1): 1-4.
8. Descouvieres C. Piso Pélvico Femenino, *Revista Chilena de Urología*. 2015; 80(2):11-17.
9. Vasileva P, Strashilov SA, Yordanov AD. Aetiology, diagnosis, and clinical management of vulvodynia. *Prz Menopauzalny*. 2020 Mar;19(1):44-48. doi: 10.5114/pm.2020.95337. Epub 2020 Apr 27. PMID: 32699543; PMCID: PMC7258372.
10. Bornstein J. 2015 ISSVD, ISSWSH and IPPS Consensus Terminology and Classification of Persistent Vulvar Pain and Vulvodynia. 2016.
11. Labat JJ, Riant T, Robert R, Amarenco G, Lefaucheur JP, Rigaud J. Diagnostic criteria for pudendal neuralgia by pudendal nerve entrapment.
12. *Neurourol Urodyn*. 2008;27(4):306-10. doi: 10.1002/nau.20505. PMID: 17828787

Enfoque sindromático de la enfermedad vulvar

REFERENCIAS BIBLIOGRÁFICAS

13. Ploteau, S., Cardaillac, C., Perrouin-Verbe, M. A., Riant, T., & Labat, J. J. (2016). Pudendal Neuralgia Due to Pudendal Nerve Entrapment: Warning Signs Observed in Two Cases and Review of the Literature. *Pain physician*, 19(3), E449–E454
14. Dargie E, Holden RR, Pukall CF. The Vulvar Pain Assessment Questionnaire inventory. *Pain*. 2016 Dec;157(12):2672-2686. doi: 10.1097/j.pain.0000000000000682. PMID: 27780177.
15. Probst D, Stout A, Hunt D. Piriformis Syndrome: A Narrative Review of the Anatomy, Diagnosis, and Treatment. *PM R*. 2019 Aug;11 Suppl 1:S54-S63. doi: 10.1002/pmrj.12189. Epub 2019 Jul 22. PMID: 31102324.
16. Seehusen DA, Johnson DR, Earwood JS, Sethuraman SN, Cornali J, Gillespie K, Doria M, Farnell E 4th, Lanham J. Improving women's experience during speculum examinations at routine gynaecological visits: randomised clinical trial. *BMJ*. 2006 Jul 22;333(7560):171. doi: 10.1136/bmj.38888.588519.55. Epub 2006 Jun 27. PMID: 16803941; PMCID: PMC1513491.
17. Hoffstetter S, Shah M. Vulvodynia. *Clin Obstet Gynecol*. 2015 Sep;58(3):536-45. doi: 10.1097/GRE.0000000000000134. PMID: 26125963.
18. Lema R, Ricci P. Atrapamiento del nervio pudendo: un síndrome por conocer. *Rev Chil OBstet Ginecol* 2006, 71 (3) 207 - 215.
19. Jantos M. Pain mapping: A mechanisms - oriented protocol for the assessment of chronic pelvic pain and urogenital pain syndromes. *Pelviperrineology* 2020; 39 (1): 3-12. DOI: 10.34057/PPj.2020.39.01.002
20. Saxena A, Chansoria M, Tomar G, Kumar A. Myofascial pain syndrome: an overview. *J Pain Palliat Care Pharmacother*. 2015 Mar;29(1):16-21. doi: 10.3109/15360288.2014.997853. Epub 2015 Jan 5. PMID: 25558924.
21. Borg-Stein J, Iaccarino MA. Myofascial pain syndrome treatments. *Phys Med Rehabil Clin N Am*. 2014 May;25(2):357-74. doi: 10.1016/j.pmr.2014.01.012. Epub 2014 Mar 17. PMID: 24787338.

Enfoque sindromático de la enfermedad vulvar

REFERENCIAS BIBLIOGRÁFICAS

22. Palma P. y Castillo O. Urofisioterapia. Aplicaciones clínicas de técnicas fisioterapéuticas en disfunciones miccionales y de suelo pélvico. Caracas 2010
23. Ramírez García I, Blanco Ratto L, Kauffmann Frau S. Rehabilitación del suelo pélvico femenino. Buenos Aires: Editorial Médica Panamericana; 2014
24. Chaitow L. Chronic Pelvic Pain and Dysfunction. London: Churchill Livingstone; 2012.
25. Probst D, Stout A, Hunt D. Piriformis Syndrome: A Narrative Review of the Anatomy, Diagnosis, and Treatment. PM R. 2019 Aug;11 Suppl 1:S54-S63. doi: 10.1002/pmrj.12189. Epub 2019 Jul 22. PMID: 31102324
26. Itza Santos F, Salinas J, Zarza D, Gómez Sancha F, Allona Almagro A. Actualización del síndrome de atrapamiento del nervio pudendo: enfoque anatómico-quirúrgico, diagnóstico y terapéutico [Update in pudendal nerve entrapment syndrome: an approach anatomic-surgical, diagnostic and therapeutic]. Actas Urol Esp. 2010 Jun;34(6):500-9. Spanish. PMID: 20510112.
27. Laso Guzmán F. Importancia de la semiología en la era tecnológica. Importancia de la semiología en la era tecnológica. 2017
28. Rosen, N. O., Bergeron, S., & Pukall, C. F. (2020). Recommendations for the Study of Vulvar Pain in Women, Part 1: Review of Assessment Tools. The journal of sexual medicine, 17(2), 180–194. <https://doi.org/10.1016/j.jsxm.2019.10.023>
29. Haanpää, M., Attal, N., Backonja, M., Baron, R., Bennett, M., Bouhassira, D., Cruccu, G., Hansson, P., Haythornthwaite, J. A., Iannetti, G. D., Jensen, T. S., Kauppila, T., Nurmikko, T. J., Rice, A., Rowbotham, M., Serra, J., Sommer, C., Smith, B. H., & Treede, R. D. (2011). NeuPSIG guidelines on neuropathic pain assessment. Pain, 152(1), 14–27. <https://doi.org/10.1016/j.pain.2010.07.031>

REFERENCIAS BIBLIOGRÁFICAS

Capítulo 25

1. Jensen TS, Baron R, Haanpää M, Kalso E, Loeser JD, Rice ASC, et al. A new definition of neuropathic pain. Vol. 152, Pain. 2011. p. 2204–5.
2. Van Hecke O, Austin SK, Khan RA, Smith BH, Torrance N. Neuropathic pain in the general population: A systematic review of epidemiological studies. Vol. 155, Pain. 2014. p. 654–62.
3. Richard L. Drake, Wayne Vogl, Adam W. M. Mitchell G. Anatomía para estudiantes (en español). España: Elsevier; 2007.
4. Tubbs RS, Miller J, Loukas M, Shoja MM, Shokouhi G, Cohen-Gadol AA. Surgical and anatomical landmarks for the perineal branch of the posterior femoral cutaneous nerve: implications in perineal pain syndromes. J Neurosurg [Internet]. 2009;111(2):332–5. Available from: <http://thejns.org/doi/10.3171/2008.11.JNS081248>
5. Maigne R and Nieves W. Diagnosis and Treatment of Pain of Vertebral Origin. Boca Raton, FL; 2006.
6. Curtis P. In Search of the “Back Mouse.” J Fam Pr. 1993;(36):657–9.
7. Elkins N, Hunt J, Scott KM. Neurogenic Pelvic Pain. Vol. 28, Physical Medicine and Rehabilitation Clinics of North America. 2017. p. 551–69.
8. Robert R, Prat-Pradal D, Labat JJ, Bensignor M, Raoul S, Rebai R, et al. Anatomic basis of chronic perineal pain: role of the pudendal nerve. Surg Radiol Anat. 1998;20(2):93–8.
9. Treede RD, Jensen TS, Campbell JN, Cruccu G, Dostrovsky JO, Griffin JW, et al. Neuropathic pain: Redefinition and a grading system for clinical and research purposes. Vol. 70, Neurology. 2008. p. 1630–5.
10. Ashton-Miller JA, DeLancey JOL. Functional anatomy of the female pelvic floor. In: Annals of the New York Academy of Sciences. 2007. p. 266–96.
11. Benson JT, Griffis K. Pudendal neuralgia, a severe pain syndrome. Am J Obstet Gynecol. 2005;192(5 SPEC. ISS.):1663–8.
12. Labat JJ, Riant T, Robert R, Amarenco G, Lefaucheur JP, Rigaud J. Diagnostic criteria for pudendal neuralgia by pudendal nerve entrapment (Nantes Criteria). Neurourol Urodyn. 2008;27(4):306–10.

Enfoque sindromático de la enfermedad vulvar

REFERENCIAS BIBLIOGRÁFICAS

13. Labat JJ, Robert R, Bensignor M, Buzelin JM. Neuralgia of the pudendal nerve. Anatomico-clinical considerations and therapeutical approach. J Urol (Paris) [Internet]. 1990;96(5):239–44. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/2230187>
14. Lefaucheur JP, Labat JJ, Amarenco G, Herbaut AG, Prat-Pradal D, Benaïm J, et al. What is the place of electroneuromyographic studies in the diagnosis and management of pudendal neuralgia related to entrapment syndrome? Vol. 37, Neurophysiologie Clinique. 2007. p. 223–8.
15. Antolak SJ, Antola CM. Chronic pelvic pain: Neurogenic or non-neurogenic? warm detection threshold testing supports a diagnosis of pudendal neuropathy. Pain Physician. 2018;21(2).
16. Antolak S. Pudendal Neuralgia. In: Potts JM, editor. Genitourinary Pain and Inflammation: Diagnosis and Management [Internet]. Springer; 2008. p. 39–56. Available from: http://www.springer.com/la/book/9781588298164?wt_mc=ThirdParty.SpringerLink.3.EPR653.About_eBook
17. Antolak SJ, Antolak CM. Therapeutic pudendal nerve blocks using corticosteroids cure pelvic pain after failure of sacral neuromodulation. Pain Med. 2009;10(1):186–9.

REFERENCIAS BIBLIOGRÁFICAS

Capítulo 26

1. Rosen, N. O., Bergeron, S., & Pukall, C. F. (2020). Recommendations for the Study of Vulvar Pain in Women, Part 1: Review of Assessment Tools. *The journal of sexual medicine*, 17(2), 180–194. <https://doi.org/10.1016/j.jsxm.2019.10.023>
2. Zhang, L., Losin, E., Ashar, Y. K., Koban, L., & Wager, T. D. (2021). Gender Biases in Estimation of Others' Pain. *The journal of pain*, 22(9), 1048–1059. <https://doi.org/10.1016/j.jpain.2021.03.001>.
3. Samulowitz, A., Gremyr, I., Eriksson, E., & Hensing, G. (2018). "Brave Men" and "Emotional Women": A Theory-Guided Literature Review on Gender Bias in Health Care and Gendered Norms towards Patients with Chronic Pain. *Pain research & management*, 2018, 6358624. <https://doi.org/10.1155/2018/6358624>
4. Torres-Cueco, R., & Nohales-Alfonso, F. (2021). Vulvodynia-It Is Time to Accept a New Understanding from a Neurobiological Perspective. *International journal of environmental research and public health*, 18(12), 6639. <https://doi.org/10.3390/ijerph18126639>
5. Haefner, H.K.; Collins, M.E.; Davis, G.D.; Edwards, L.; Foster, D.C.; Hartmann, E.H.; Kaufman, R.H.; Lynch, P.J.; Margesson, L.J.; Moyal-Barracco, M.; et al. The Vulvodynia Guideline. *J. Low. Genit. Tract Dis.* 2005, 9, 40–51.
6. Raja SN, Carr DB, Cohen M, Finnerup NB, Flor H, Gibson S, et al. The revised International Association for the Study of Pain definition of pain: concepts, challenges, and compromises. *Pain*. 2020. DOI: 10.1097/j.pain.0000000000001939.
7. Micheletti, L.; Radici, G.; Lynch, P.J. Provoked vestibulodynia: Inflammatory, neuropathic or dysfunctional pain? A neurobiological perspective. *J. Obstet. Gynaecol.* 2014, 34, 285–288.
8. Rosen, N. O., Dawson, S. J., Brooks, M., & Kellogg-Spadt, S. (2019). Treatment of Vulvodynia: Pharmacological and Non-Pharmacological Approaches. *Drugs*, 79(5), 483–493. doi:10.1007/s40265-019-01085-1
9. Fuente: <https://www.issvd.org/publications>

Enfoque sindromático de la enfermedad vulvar

REFERENCIAS BIBLIOGRÁFICAS

REFERENCIAS BIBLIOGRÁFICAS

Capítulo 27

1. Lucente, Vincent, Van Raalte Heather, Murphy Miles. *Biomechanical paradigm and interpretation of female pelvic floor conditions before a treatment*. International Journal of Women's Health. 2017, Vol. 9: 521-550
2. Petros P. *The Female Pelvic Floor: Function, Dysfunction and Management According to the Integral Theory*. 3rd ed. Berlin, Germany: Springer; 2010:1–330.
3. Lee, D., Lee, L.J., McLaughlin, L. Stability, continence and breathing: The role of fascia following pregnancy and delivery. J. Bodyw. Mov. Ther. 2008, Vol. 12 (4), 333–348
4. Gibbons, S.G.T. The model of psoas major stability function. In: Proceedings of 1st International Conference on Movement Dysfunction, 2001, Sept 21–23, Edinburgh, Scotland
5. Rochera Mercedes. *Fisioterapia en las disfunciones sexuales femeninas*. 2010. Madrid – España.
6. Ahangari A. *Prevalence of chronic pelvic pain among women: an updated review*. Pain Physician. 2014, Vol. 17 (2), 141-147
7. Allaire Catherine; Williams Christin. *Chronic pelvic pain in an interdisciplinary setting: 1-year prospective cohort*. American Journal of Obstetrics & Gynecology 2017, Vol. 218 (1), 114-117
8. Peters AA, van Dorst E, y cols. A randomized clinical trial to compare two different approaches in women with chronic pelvic pain. Obstet Gynecol 1991, Vol.77 (5), 740-744
9. Haugstad GK, Haugstad TS, y cols. Mensendieck somatocognitive therapy as treatment approach to chronic pelvic pain: results of a randomized controlled intervention study. Am J Obstet Gynecol 2006, Vol. 194 (5), 1303-1310
10. Da Ros Carlos, G.T, *Urofisioterapia*. Caracas: paulo Palma 2010
11. Frank F. Tu, Holt Jane. Physical therapy evaluation of patients with chronic pelvic pain: a controlled study. American Journal of Obstetrics & Gynecology 2008, Vol.198 (3), 272-277

Enfoque sindromático de la enfermedad vulvar

REFERENCIAS BIBLIOGRÁFICAS

12. Diatchenko L, Nackley AG y cols. Idiopathic pain disorders: pathways of vulnerability. *Pain* 2006, Vol. 123 (3), 226-230
13. Fitzgerald MP, Anderson RU. Randomized multicenter feasibility trial of myofascial physical therapy for the treatment of urological chronic pelvic pain syndromes. *J Urol* 2009 Vol, 182 (2), 570-580
14. Rost CC, Jacqueline J, Kaiser A. Prognosis of women with pelvic pain during pregnancy: a long-term follow-up study. *Acta Obstet Gynecol Scand* 2006, Vol. 85 (7), 771-777
15. Thiele GH: Coccygodynia and pain in the superior gluteal region. *JAMA*. 1937, Vol. 109 (16) 1271-1275
16. Oyama IA, Rejba A, Lukban JC. Modified Thiele massage as therapeutic intervention for female patients with interstitial cystitis and high-tone pelvic floor dysfunction. *Urology*. 2004 Vol: 64 (5), 862-865
17. Loving S. Does evidence support physiotherapy management of adult female chronic pelvic pain? A systematic review. *Scandinavian Journal of Pain*. 2012, Vol.3 (2), 70-81
18. Travell W, Travell J. Technique for reduction and ambulatory treatment of sacroiliac displacement. *Arc Phys Ther*. 1942
19. Travell y Simons. Dolor y Disfunción miofascial. El manual de los puntos gatillo volumen 2, extremidades inferiores. Abril 2010
20. Weiss, J.M. Pelvic floor myofascial trigger points: manual therapy for interstitial cystitis and the urgency-frequency syndrome. *J. Urol*. 2001
21. Srinivasan, A.K., Kaye. Myofascial dysfunction associated with chronic pelvic floor pain: management strategies. *Curr. Pain Headache Rep*. 2007, Vol, 166 (6) 2226-2231
22. Dommerholt, J., McEvoy, J. Myofascial trigger point release approach. In: Wise, C.H. (Ed.), *Orthopaedic manual physical therapy: from art to evidence*. 2010. Capítulo 21, 247-259
23. Montenegro, L.L.S., Gomide, L.B. Abdominal myofascial pain syndrome must be considered in the differential diagnosis of chronic pelvic pain. *Eur. J. Obstet Gynecol Reprod. Biol* 2009, Vol. 147 (1), 21-24
24. Chaitow Leon, Jones Ruth. *Chronic Pelvic Pain and dysfunction*. Elsevier 2012.

REFERENCIAS BIBLIOGRÁFICAS

25. Pool-Goudzwaard, A. Contribution of pelvic floor muscles to stiffness of the pelvic ring. Clin. Biomech. 2004, Vol. 19 (6), 564-571.
26. Peschers, U.M., DeLancey. Therapeutic management of incontinence and pelvic pain. Ed Springer. 2008
27. Jantos, M. Vulvodynia:a psychophysiological profile based on electromyographic assessment. Appl. Psychophysiol. Biofeedback 2008. Vol. 33 (1), 29-38
28. Oleksy, Ł., Wojciechowska, M., Mika, A., Antos, E., Bylina, D., Kielnar, R., Pruszczyński, B., & Stolarczyk, A. (2020). Normative values for Glazer Protocol in the evaluation of pelvic floor muscle bioelectrical activity. *Medicine*, 99(5), e19060. <https://doi.org/10.1097/MD.00000000000019060>

REFERENCIAS BIBLIOGRÁFICAS

Capítulo 28

1. Asociación de Ginecólogos Estéticos Colombianos – AGEOC
2. Todone. A. Cirugía Estética, Reconstructiva y Rediseño Vulvovaginal. Médico Cirujano Ginecólogo y Jefe de la Sección de Uroginecología y Piso Pelviano. Hospital General de Agudos “JM Ramos Mejía”- CABA
3. Rodríguez. D. La cirugía plástica en Colombia: ¿una obligación de medios o de resultado? Universidad ces facultad de derecho Colombia.
4. Lezana, J. Responsabilidad Profesional de los Médicos. Buenos Aires: Ed Corporación Universitaria del este. (2005).
5. La Cirugía Plástica. Sociedad Colombiana de Cirugía Plástica, disponible en www.cirugiaplastica.org.co. (2013, 9 de septiembre).
6. Guzmán, M. Obligación de medio. Bogotá D.C: Ed. Empresa Editorial de Cundinamarca. (2013).
7. Ley N. 1799 del 25 julio 2016. Por medio de la cual se prohíben los procedimientos médicos y quirúrgicos estéticos para menores de edad y se dictan otras disposiciones. Congreso de Colombia.

REFERENCIAS BIBLIOGRÁFICAS

Capítulo 29

1. Yahrz Wz, Strully KJ: Blood vessel anastomosis by laser and other biomedical Applicational. J Assoc Adv Med Instrum 1966; 1: 28-31
2. Jako Gj: Laser surgery of the vocal cords: an experimental study with carbon dioxide Lasers on dogs. Laryngoscope 1972; 82: 2204-2216
3. Kaplan I, Goldman J, The treatment of erosions of the uterine cervix by Means of the CO₂ laser. Obstet Gynecol 1973; 41: 795-796
4. Bellina Jh: Gynecology and the laser. Contemp Obste: Gynecol 1974; 4: 24-34
5. Anderson RR, Parrish JA. Selective photothermolysis: precise microsurgery by selective absorption of pulsed radiation. Science 1983;220:524– 527.
6. Salvatore, MD; Maurizio Serati, MD; Gabriele Siesto, MD; Massimo Origoni, MD; Masimo Candiani, Professor; Alberto Calligaro, Professor; Nicola Zerbinati, MDEJOGRB-12-9070
7. Bachman, G. A. (1997), “A new option for managing urogenital atrophy in postmenopausal women”, *Cont Obstet Gynecol*, 42, pp. 13-28.
8. Ronconi, L. & Galli, M. (2012), MonaLisa Touch™: The Latest Frontier in the Treatment of Vaginal Atrophy, DEKA Ed. , Scientific Series, vol. 2.
9. Gaspar, A. ; Addamo, G. & Brandi, H. (2011), “Vaginal Fractional CO₂ Laser: A Minimally Invasive Option for Vaginal Rejuvenation”, *Am J Cosm Surg*, 28 (3), pp. 156-162
10. Salvatore, S. ; Nappi, R. E. ; Zerbinati, N. ; Calligaro, A. ; Ferrero, S. ; Candiani, M. & Maggiore, U. L. (2014), “A 12-week treatment with fractional CO₂ laser for vulvovaginal atrophy: a pilot study”, *Climacteric*, Epub Mar 8, PubMed PMID: 24605832.
11. Annalisa Pieralli Maria Grazia Fallan, Fractional CO₂ laser for vulvovaginal atrophy (VVA) dyspareunia relief in breast cancer survivors, Arch Gynecol Obstet DOI 10. 1007/s00404-016-4118-6
12. M. Gambacciani, M. Levancini, Mauro Cervigni Vaginal erbium laser: the second-generation thermotherapy for the genitourinary syndrome of menopause DOI: 10. 3109/13697137. 2015. 1045485

Enfoque sindromático de la enfermedad vulvar

REFERENCIAS BIBLIOGRÁFICAS

13. Monsálvez, V. ; Rivera R. ; Vanaclocha, F. : Liquen escleroso. Actas Dermosifiliogr 2010; 101: 31-38
14. Lee, A, Lim. A: Fractional CO₂ laser in recalcitrant Vulval lichen Sclerosus Australasian Journal of Dermatology
15. Int J Womens Dermatol. 2016 Dec 6;3(2):77-85. doi: 10. 1016/j. ijwd. 2016. 11. 001. eCollection 2017 Jun
16. Becorpi. A. Fractional CO₂ laser for genitourinary syndrome of menopause in breast cancer survivors: clinical, immunological, and microbiological aspects Lasers in Medical Science <https://doi.org/10.1007/s10103-018-2471-3>.
17. Athanasiou S, Pitsouni E, Antonopoulou S, Zacharakis D, Salvatore S, Falagas ME, Grigoriadis T (2016) The effect of microablative fractional CO₂ laser on vaginal flora of postmenopausal women. Climacteric: the journal of the International Menopause Society 19(5):512–518. <https://doi.org/10.1080/13697137.2016.1212006>
18. Laser de CO₂ fraccionado, un nuevo enfoque de tratamiento para la incontinencia urinaria de esfuerzo (IUE) en mujeres post menopausicas Revista Colombiana de Urología (10)Sept Dic 2016
19. Pablo Gonzalez Isaza, Kinga Jajaguszewska, mariusz lutkazuk, jose Luis Cardona, Long-term effect, of thermoablative Fractional CO₂ Laser treatment as a novel approach, to urinary incontinence management in women with genitourinary syndrome of menopause, Interna Urogyn Jour 2017 June
20. Rouzzier R, Louis S, Paniel C. Hypertrophy of labia minora: Experience with 163 reductions. Am J Obstet Gynecol 2000;(1 PT 1):35-40.
21. Maas SM, Hage JJ. Functional and aesthetic labia minora reduction. Plastic Reconstr Surg 2000;105:(14):53-56.
22. Pardo J, Sola V, Ricci P, Guilloff E. Laser labioplasty of the labia minora. Int J Gynaecol Obstet 2006;(93):38-43.

Capítulo 30

1. Cisneros-Vela JL, Camacho-Martínez F. Láser. Fuentes de luz pulsada intensa en dermatología y dermocosmética. Primera ed. Madrid-España: Amolca; 2002.
2. Stewart N, Lim AC, Lowe PM, Goodman G. Lasers and laser-like devices: part one. *Australasian Journal of Dermatology*. 2013; 54(3):173–183
3. Geiges ML. History of lasers in dermatology. *Curr Probl Dermatol*. 2011; 42: 1–6.
4. Houk LD, Humphreys T. Masers to magic bullets: an updated history of lasers in dermatology. *Clin Dermatol*. 2007; 25(5):434–42.
5. Zaret MM, Breinin GM, Schmidt H, Ripps H, Siegel IM, Solon LR. Ocular lesions produced by and optical maser (laser). *Science*. 1961; 134(3489):1525–6.
6. Goldman L, Blaney DJ, Kindel DJ Jr, Richfield D, Franke EK. Pathology of the effect of the laser beam on skin. *Nature*. 1963; 197:912–4.
7. Manstein D, Herron GS, Sink RK, Tanner H, Anderson RR. Fractional photothermolysis: a new concept for cutaneous remodelling using microscopic patterns of thermal injury. *Lasers Surg Med*. 2004; 34(5):426–38.
8. Manstein D, Laubach H, Watanabe K, Farinelli W, Zurakowski D, Anderson RR. Selective cryolysis: a novel method of non-invasive fat removal. *Lasers Surg Med*. 2008; 40(9): 595–604.
9. Wheeland RG. History of lasers in dermatology. *Clin. Dermatol*. 1995; 13(1):3–10.
10. DiBernardo BE, Cacciarelli A. Cutaneous lasers. *Clin Plastic Surg*. 2005; 32(2): 141–150.
11. Goldman MP, Fitzpatrick RE, Ross EV, Kilmer SL, Weiss RA. Lasers and energy devices for the skin. Second Ed. Boca Raton: CRC Press; 2013. p. 1–31.
12. Arredondo MI, Vásquez LA, Arroyave JE, Molina V, Del Río DY, Herrera J. Láser en dermatología. *Rev Asoc Colomb Dermatol*. 2014; 22(2): 111–125.
13. Bodgan Alleman I, Kaufman J. Fractional photothermolysis-an update. *Lasers Med Sci*. 2010; 25(1):137–44.
14. Saedi N, Jalian HR, Petelin A, Zachary C. Fractionation: past, present and future. *Semin Cutan Med Surg*. 2012; 31(2):105–9.

Enfoque sindromático de la enfermedad vulvar

REFERENCIAS BIBLIOGRÁFICAS

15. Goel A, Krupashankar DS, Aurangabadkar S, Nischal KC, Omprakash HM, Mysore V. Fractional lasers in dermatology - -current status and recommendations. *Indian J Dermatol Venereol Leprol*. 2011; 77(3):369-79.
16. Gold MH. Update on fractional laser technology. *J Clin Aesthet Dermatol*. 2010; 3(1):42-50.
17. Jih MH, Kimyai-Asadi A. Fractional photothermolysis: a review and update. *Semin Cutan Med Surg*. 2008; 27(1):63-71.
18. Kaushik SB, Alexis AF. Nonablative fractional laser resurfacing in skin of Color: evidence-based review. *J Clin Aesthet Dermatol*. 2017; 10(6):51-67.
19. Gambacciani M, Palacios S. Laser therapy for the restoration of vaginal function. *Maturitas*. 2017; 99:10-15.
20. Vizintin Z, Lukac M, Kazic M, Tettamanti M. Erbium laser in gynecology. *Climateric*. 2015; 18(Suppl 1):4-8.
21. Barbara G, Facchin F, Buggio L, Alberico D, Frattaruolo MP, Kustermann A. Vaginal rejuvenation: current perspectives. *Int J Womens Health*. 2017; 9:513-519.

REFERENCIAS BIBLIOGRÁFICAS

Capítulo 31

1. Illingworth, B. J. G., Stocking, K., Showell, M., Kirk, E., & Duffy, J. M. N. (2019). Evaluation of treatments for Bartholin's cyst or abscess: A systematic review. *BJOG: An International Journal of Obstetrics & Gynaecology*. doi:10.1111/1471-0528.16079
2. Kamilos MF, Borrelli CL, Sciuto R, Cotrim FP, Veiga ECA, Soares Júnior JM, Tacla M, Baracat EC. Is electrosurgery fulguration a better procedure for Bartholin's gland cyst? *Rev Assoc Med Bras* (1992). 2020 May 15;66(2):201-209. doi: 10.1590/1806-9282.66.2.201. PMID: 32428156.
3. Kamilos, M. F., & Borrelli, C. L. (2017). New therapeutic option in genitourinary syndrome of menopause: pilot study using microablative fractional radiofrequency. *Einstein (Sao Paulo, Brazil)*, 15(4), 445–451. <https://doi.org/10.1590/S1679-45082017AO4051>
4. Kamilos, M. F., Aguiar, L. M., Batista, V. H., Roa, C. L., Aguiar, F. N., Soares Júnior, J. M., & Baracat, E. C. (2021). Microablative fractional radiofrequency as a therapeutic option for vulvar lichen sclerosus: a pilot study. *Clinics (Sao Paulo, Brazil)*, 76, e2567. <https://doi.org/10.6061/clinics/2021/e2567>

REFERENCIAS BIBLIOGRÁFICAS

Capítulo 32

1. Jos F, Hoz E La. PREVALENCE AND CHARACTERISATION OF SEXUAL DYSFUNCTIONS IN WOMEN , IN 12 COLOMBIAN CITIES , 2009-2016 Prevalencia y caracterización de las disfunciones sexuales en mujeres , en 12 ciudades colombianas , 2009-2016. 2018;69(1):9–21.
2. Porst H, Reisman Y. The ESSM Syllabus of Sexual Medicine. 2012;(I).
3. Vallejo-Medina P, Gómez-Lugo M, Marchal-Bertrand L, Saavedra-Roa A, Soler F, Morales A. Developing guidelines for adapting questionnaires into the same language in another culture. *Ter Psicológica*. 2017;35(2):159–72.
4. Bobes, M. P. Gonzalez, F. Rico-Vill J. Validation of the Spanish Version of the Changes in Sexual Functioning Questionnaire (CSFQ). *J Sex Marital Ther* [Internet]. 2000;26(2):119–31. Available from: <http://www.tandfonline.com/doi/abs/10.1080/009262300278524>
5. Soler F, Lugo MG, Espada JP, Morales A, Sierra JC, Bertrand LM, et al. Adaptation and Validation of the Brief Sexuality Scale in Colombian and Spanish Populations. *Int J Psychol Psychol Ther*. 2016;16(3):343–56.
6. Vallejo-Medina P, Marchal-Bertrand L, Gomez-Lugo M, Espada JP, Sierra JC, Soler F, et al. Adaptation and validation of the brief sexual opinion survey (SOS) in a colombian sample and factorial equivalence with the Spanish version. *PLoS One*. 2016;11(9):1–14.
7. Marchal-Bertrand L, Espada JP, Morales A, Gómez-Lugo M, Soler F, Vallejo-Medina P. Adaptation, validation and reliability of the Massachusetts General Hospital-Sexual Functioning Questionnaire in a Colombian sample and factorial equivalence with the Spanish version. *Rev Latinoam Psicol*. 2016;48(2):88–97.
8. Dentro AC, Lengua M, Cultura O, Psicol T. Versión validada en Colombia de la Sexual Assertiveness Scale (SAS ; Morokoff et La presente escala tiene como objetivo evaluar la percepción o aprecio que tiene usted acerca de su comportamiento sexual . Por favor , marque su grado de acuerdo/desacuer. 2017;(62):4–5.
9. Vallejo-Medina P, Pérez-Durán C, Saavedra-Roa A. Translation, Adaptation, and

Enfoque sindromático de la enfermedad vulvar

REFERENCIAS BIBLIOGRÁFICAS

- Preliminary Validation of the Female Sexual Function Index into Spanish (Colombia).
Arch Sex Behav. 2018;47(3):797–810.
10. Validation P, Sexual F, Index F, Behavior S. 1.2 Versión validada en Colombia del The Female Sexual Function Index (FSFI; Rosen et al., 2000). 2017;(61).
 11. MESTON CM. Validation of the Female Sexual Function Index (FSFI) in Women with Female Orgasmic Disorder and in Women with Hypoactive Sexual Desire Disorder. J Sex Marital Ther. 2003.